University of Texas at El Paso

DigitalCommons@UTEP
Open Access Theses & Dissertations

2019-01-01

Application Of Urinary Metabolites For Cancer
Detection
Qin Gao
University of Texas at El Paso, qingaocn@live.com

Follow this and additional works at: https://digitalcommons.utep.edu/open_etd
Part of the Analytical Chemistry Commons, and the Statistics and Probability Commons
Recommended Citation
Gao, Qin, "Application Of Urinary Metabolites For Cancer Detection" (2019). Open Access Theses & Dissertations. 72.
https://digitalcommons.utep.edu/open_etd/72

This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations
by an authorized administrator of DigitalCommons@UTEP. For more information, please contact lweber@utep.edu.

APPLICATION OF URINARY METABOLITES FOR CANCER DETECTION

Qin Gao
Doctoral Program in Chemistry

APPROVED:

Wen-Yee Lee, Ph.D., Chair

Marc B. Cox, Ph.D.

Chu Young Kim, Ph.D.

Xiaogang Su, Ph.D.

Charles Ambler, Ph.D.
Dean of the Graduate School

Copyright ©

by
Qin Gao
2019

Dedication

To my
Parents
with love

APPLICATION OF URINARY METABOLITES FOR CANCER DETECTION

by

Qin Gao.

DISSERTATION

Presented to the Faculty of the Graduate School of
The University of Texas at El Paso
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHILOSOPHY

Department of Chemistry and Biochemistry
THE UNIVERSITY OF TEXAS AT EL PASO
May 2019

Acknowledgements
In my five years of studying at the University of Texas at El Paso (UTEP), I am privileged
that I met many wonderful people in different fields, who help me pursue my dream of being a
researcher.
I would like to express my deepest gratitude to my mentor, Dr. Wen-Yee Lee, for
introducing me to the research field of analytical chemistry and clinical cancer research, and for
her guidance, encouragement, enduring patience and constant support. Her dedication and
motivation to research will continue to inspire me. Moreover, her commitment to the professional
development of her students is impressively remarkable. Dr. Lee is always pleased to provide
opportunities for her students to give presentations in all kinds of conferences, and provide strong
recommendation letters whenever she is needed. Her helpful guidance equips me with competency
in research, improve my scientific writing skills, and produce notable scientific publications and
patents. I also really appreciate Dr. Lee’s concern, encouragement, and plan for my professional
development.
I am grateful to all my committee members: Dr. Marc B. Cox, Dr. Chu Young Kim, and
Dr. Xiaogang Su. With distinct scientific backgrounds, they have provided numerous helpful
advice, insight, and suggestions with their kindness and valuable time. I especially want to thank
Dr. Su, with whom we have ongoing collaborations. Dr. Su’s strong support of statistics was
essential for my research.
I appreciate the support of my colleagues in the Dr. Lee’s Research Group. In particular, I
would like to thank those who helped me: Angela Encerrado Manriquez, Alma L Loya, and Tianqi
Xiang. Other colleagues are likewise very much appreciated for their readiness to help and for the
nice working atmosphere they created.
I would like to thank all the professors and staffs from Department of Chemistry and
Biochemistry of UTEP for all their hard work and dedication, providing me the knowledge and
means to complete my degree. I would like to express special thanks to Dr. River and Dr. Cox for
v

providing the access to use the equipment for my experiments. I would also like to thank Dr.
Heinric Williams from Geisinger Medical Center (PA) and Dr. Annabi from the Clinic Internal
Medicine (El Paso, TX) for providing the human clinical samples for prostate cancer and renal
cancer diagnosis.
I want to thank my dear parents, my grandparents, my uncles, my aunts, and all my dear
friends for their true love, encouragement, and firm support. It was impossible for me to continue
my graduate study without them.
The funding agencies that supported my dissertation research are very much appreciated. I
would like to acknowledge the financial support of the Graduate School (Dodson Research Grant),
College of Science (Wiemer Family Student Endowment for Excellence), and Dr. Keelung Hong
Gift Fund for VOC Cancer Research Studies and Chemistry Graduate Research Fellowship .Travel
grant support from the Graduate School, College of Science, Department of Chemistry and
Biochemistry and Student Government Association of UTEP is also gratefully acknowledged.

vi

Abstract
Prostate cancer (PCa) is the 3rd most common cause of male cancer mortality in the US.
Early diagnosis and treatment of PCa will improve the quality of care and reduce mortality. The
prostate specific antigen (PSA) is commonly used in the current PCa screening, but its limitation
has resulted in an intense search for more reliable biomarkers. Studies showed that dogs could
differentiate PCa patients from negative control by sniffing their urine. As the odor profiles are
generated by volatile organic compounds (VOCs), the finding suggests that particular VOCs could
be linked to PCa, PCa risk levels and other cancers. Therefore the overarching goal of study was
to develop a reliable, quick and patient-friendly diagnostic method for PCa screening to replace
the current PSA testing and avoid unnecessary biopsy. The objectives of this study were 1) to
develop and validate a urinary VOCs based model for PCa diagnosis; 2) to study the performance
of urinary VOCs in differentiating high/intermediate PCa patients from low risk PCa patients; 3)
to investigate the urinary VOCs for the early screening of other urological cancer, such as clear
cell renal cell carcinoma (ccRCC); and 4) to evaluate the specificity of urinary VOCs models in
PCa and ccRCC detection.
In the study of the PCa urinary VOCs profile, a VOCs based PCa model was developed
and validated. Urine samples from 55 and 53 biopsy proven PCa positive and negative patients
respectively were obtained for diagnostic model development. Urinary metabolites were analyzed
by Stir Bar Sorptive Extraction coupled with Gas Chromatography-Mass Spectrometry. A PCa
diagnosis model was developed and validated using innovative statistical machine-learning
techniques. The analysis resulted in 254 and 282 VOCs for their significant association (p<0.05)
with either PCa positive or negative samples respectively.

Regularized logistic regression

analysis and the Firth method were then applied to predict PCa prevalence, resulting in a final
model that contained 11 VOCs. Under cross-validation, the area under the receiver operating
characteristic curve (AUC) for the final model was 0.92 (sensitivity: 0.96; specificity: 0.80).
Further evaluation of the developed model using a testing cohort yielded an AUC of 0.86. As a
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comparison, the PSA-based diagnosis model of the same cohort of patients only rendered an AUC
of 0.54.
Then, since the performance of VOCs was proved to be able to strongly discriminate PCa
patients from controls, we hypothesized that urinary VOCs could be used to develop urinary VOC
PCa prognostic models for cancer risk assessment. PCa is a heterogeneous disease ranging from
indolent to life threatening stages. Another VOCs based PCa risk assessment model was developed
through comparing high/intermediate risk patients with low risk patients. Based on the D’Amico
risk scores system, these PCa patients were divided into two groups: 55 in low-risk group (indolent
PCa, GS = 6, PSA< 10) and 34 in high/intermediate-risk group (clinically significant PCa, GS = 6
and PSA ≥ 10, or GS > 6 with any PSA values). Urine samples from 89 men who presented for
transrectal ultrasound guided prostate biopsy for an elevated PSA or abnormal digital rectal exam
were collected. Using the Wilcoxon rank sum test, 23 VOCs were found to be positively related
to high/intermediate−risk PCa and 44 VOCs negatively associated. Regularized logistic regression
analysis and the Firth method were then applied to predict PCa risk level, resulting in a final model
that contained 11 VOCs. Under cross-validation, the area under the receiver operating
characteristic curve (AUC) for the final model was 0.86 (sensitivity: 0.85; specificity: 0.80), which
indicates a highly promising discrimination power of urinary VOCs in PCa high/intermediate risk
assessment.
To test the performance of VOCs in other genitourinary cancers, we investigated the
urinary VOCs profile of clear cell renal cell carcinoma (ccRCC the main type of renal cell
carcinoma, RCC). The fast and reliable early screen of RCC enables better outcome and
predication in patients. However, there is no recommended screening tests for RCC available
clinically. A total of 108 urine samples were obtained from 71 patients who were undergoing
partial or radical nephrectomy and 37 patients ccRCC negative based the imaged renal mass to
identify the specific VOCs in urine for ccRCC screening. The VOCs based ccRCC diagnostic
model was developed through the logistic regression in training set (57 ccRCC vs 31 controls) and
validated in another testing set group (14 RCC vs 6 controls). A total of 8,266 VOCs were found
viii

in the urine samples of training set. Using Wilcoxon Rank Sum Test in screening their bivariate
association with ccRCC, 79 VOCs were found to be related to urine samples of ccRCC patients
while 91 VOCs corresponding to RCC negative controls with statistical significance at p =0.05.
After further selection with 𝑙1 regularization, 15 VOCs were included in the RCC diagnostic
logistic model. On the basis of predicted probabilities from the model via cross-validation, the area
under the receiver operating characteristic curve (AUC) was found to be 0.87 and the sensitivity
and specificity were 93% and 77% respectively. The VOCs based RCC diagnostic model were
then validated in testing group. The results showed a promising diagnostic power of this VOCs
model in ccRCC screening with AUC of 0.81, with 86% sensitivity and 83% specificity
respectively.
Moreover, we cross examined the performance of the two PCa and ccRCC VOCs models.
Four cohorts from the previous studies were involved in this analysis. The four groups contained
(1) 55 PCa positive patients, PCa (+), (2) 53 PCa negative patients, PCa (-), (3) 55 ccRCC positive
patients, ccRCC (+), and (4) 31 RCC negative patients, ccRCC (-). For the PCa model was cross
examined between PCa (+) and the rest of the three groups combined, and the result showed an
AUC of 0.834 with confidence interval 0.779 to 0.889. Then, the ccRCC model was validated
through comparing ccRCC (+) with the rest of the three groups combined.

The validation

rendered an AUC of 0.779 with confidence interval 0.707 to 0.851. The cross evaluation verified
the discrimination power of those 11 VOCs based PCa model and 15 VOCs based ccRCC model
even in more complicated patients.
The investigations among PCa and ccRCC demonstrate and validate the clinical utility of
a non-invasive urinary VOCs based diagnostic model in PCa and ccRCC screening. The VOCs
based diagnostic model has the substantial potency and clinical value in PCa and RCC screening,
and the analytical method was fast and highly translatable.
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Chapter 1: Introduction

1

1.1

VOCs emitted from human body
Volatile organic compounds (VOCs), the majority being organic in nature, are

continuously generated in human body and released through breath, blood, skin, urine and fecal
samples (Figure 1. 1).1-4 These VOCs carry information of the physiological and metabolic status
of the individual.5 Furthermore, the VOCs emitted from different areas of the human body vary
with age, diet, sex, physiological status and possibly genetic background. Therefore, body odors
containing VOCs can be considered as individual ‘odor-fingerprints’.6

Figure 1. 1 Continuously generated from human body and released through breath, blood, skin,
urine and feces. (Source: M. Shirasu and K. Touhara, 2011. Copyright © 2011 The Journal of
Biochemistry.6)
As VOCs are considered the metabolites of biological activities in human body, they exist
in various parts of our system. Furthermore, pathological processes, occurring as a consequence
of disease, can alter the production of specific VOCs which the body generates differently during
2

normal biological processes. In recent studies have demonstrated that sniffer dogs can differentiate
cancer patients from control negative by sniffing their biological samples, such as urine.7-10
Therefore, we can use VOCs as a predictive biomarker for disease detection.

A) VOCs in Blood
The specific VOCs in the blood have been reported to be useful in predicting and
diagnosing diseases, such as ovarian cancer, colorectal cancer, lung cancer, and hepatic
encephalopathy.11-14 In the study of Horvath et al.11, the trained dogs can differentiate ovarian
cancer patients from the patients with other gynecological cancers and healthy control subjects
through sniffing the blood samples from patients. And Wang et al.12 carried out a study to identify
the blood volatile compounds as biomarkers for colorectal cancer by collecting blood samples
from 16 colorectal cancer patients and 20 healthy controls. Four metabolic biomarkers were found
at significantly higher or lower level cancer patients. Further studies are needed to evaluate these
results and to apply these findings to clinical diagnoses. Blood directly reflects the internal
environment of the body, including nutritional, metabolic and immune status, which highly values
the blood samples in disease-specific VOCs studies. However, obtaining blood samples is invasive
and not easy due to the onus on patients, and pre-treatment of blood samples is also timeconsuming. All of these factors have limited the use of VOCs in blood for diagnostic tool
development.

B) VOCs in Breath
Exhaled breath contains VOCs that can be attributed to either exogenous or endogenous
volatiles15,16. Endogenous volatiles consist of blood-borne compounds released to the environment
via the lungs and/or compounds made from all classes of symbiotic bacteria. Numerous studies
were conducted to investigate the potential of VOCs in breath in diseases diagnosis, especially
lung cancer. Collecting breath samples is relatively simple, painless and non-invasive as compared
to sampling blood. Phillips et al.17 collected breath samples from 108 patients and a combination
3

of 22 VOCs in breath samples distinguished between patients with and without lung cancer. In the
study of Peng et al.18, an array of sensors based on gold nanoparticles were shown to be able to
rapidly distinguish the breath of lung cancer patients from the breath of healthy individuals in an
atmosphere of high humidity by training and optimizing sensors with the VOCs identified through
gas chromatography/mass spectrometry (GC-MS).

However, it is always challenging to

distinguish contaminant environmental exogenous compounds from endogenously produced
VOCs. Exogenous volatiles include compounds inhaled from the external environment, such as
compounds produced following the oral ingestion of food and compounds derived from smoking
cigarettes.

C) VOCs in Urine
The VOCs in urine are intermediate products or end products of a number of metabolic
pathways, which may contain a variety of structural motifs with a particular odor, such as ketone,
alcohol, furan, pyrrole and sulphide.6 In some cases, characteristic urine VOCs profile have been
directly linked to particular metabolic disorders. Some studies have been conducted to illustrate
urinary VOCs profiles in infectious diseases19,20 and different types of cancers, including prostate
cancer (PCa)21, renal cancer (RCa)22 and bladder cancer (BCa)23.
Urinary VOC patterns in cancer patients are often different from the patterns in urine
samples from control subjects, although the differences depend on cancer types and even cancer
stages. Khalid et al.21 showed that urinary VOCs profile of prostate cancer patients can be
discriminated from cancer free controls by using four VOCs, 2,6-dimethyl-7-octen-2-ol, pentanal,
3-octanone, and 2-octanone with accuracy as high as 71%. In an analysis of volatile human urinary
metabolome for renal cell carcinoma (RCC), Monteiro et al.22 reported a new and simple analytical
approach developed to study the volatile human urinary metabolome and the results clearly showed
the potential of volatile urinary metabolome to discriminate between RCC and control patients
with 60.33% of the variability in principal component analysis (PCA). And according to Weber et
al.23, the best diagnostic performance they obtained through the comparison between healthy
4

volunteers and bladder cancer patients was 70% overall accuracy using a gas sensor array and
pattern recognition.
These studies have proved the potential in searching for volatile diagnostic biomarkers in
the urine of cancer patients. Due to the complexity of urine components, such as metabolites from
ingested foods and drinks, and considerable variation among individuals, caution must be taken
when determining whether or not a candidate VOC biomarker results from disease-related changes
in metabolism and advanced computer processing of chromatographic data should be involved in
identifying the VOC patterns.

D) Others
VOCs can also be continuously emitted from skin surface as sweat. Sweat is one of the less
employed bio-fluids for discovery of markers. In the research conducted by Calderón-Santiago et
al.24, human sweat was collected and used as clinical sample to develop a screening tool for lung
cancer. The capability of the metabolites identified in sweat to discriminate between patients with
lung cancer versus smokers as control individuals was studied. The five metabolites identified in
this study provided 80 % specificity and 79 % sensitivity. Mi-Jung et al.25 also applied the analysis
of sweat volatile organic compounds in forensic science. Although some of these VOCs result
from internal hormonal or metabolic changes, many VOCs appear to be derived from symbiotic
bacteria that live on the skin surface and metabolize and transform secreted compounds in sweat
and sebum. Any alteration in homeostatic balance due, for instance, to some inherited metabolic
disorder or bacterial infection of the diseased area can induce changes in both the quality and
quantity of VOCs. For example, some infectious diseases or cancerous wounds develop
characteristic and offensive odors.6 Meanwhile, the contamination from the environment must also
be taken into consideration, including the interference from the ambient air, humidity and
cosmetics.
Human fecal samples represent dietary end-products resulting from digestive and excretory
processes and intestinal bacterial metabolism. The investigation of fecal VOCs may reveal
5

potential health consequences and be the best non-invasive way of diagnosing gastrointestinal
diseases. Distinct patterns of VOCs have been associated with fecal samples from patients with
some types of bacterial infection, such as Vibrio cholera, , Clostridium difficile or Campylobacter
jejuni infections.26,27. Batty et al.28 reported the use of volatile fecal metabolome in screening for
colorectal cancer with 78% specificity and 72% sensitivity. VOCs may also be contained in other
types of bio-fluids, such as vaginal secretions, which accurately reflect the stages of menstrual
cycles
In summary, VOCs can be emitted from different types of biological samples of human
body and carry “odor fingerprint” of the individual (Table 1. 1). Pathological processes, such as
infection and endogenous metabolic disorders, can influence our daily odor fingerprints by
producing new VOCs or by changing the ratio of VOCs that are produced normally. 6 And that is
why these VOCs could potentially be attractive to physicians, physiologist, and surgeons as
potential aids to clinical diagnosis and therapeutic monitoring. However, those VOCs may be
affected by various factors, such as age, sex, drug therapy, diet and smoking. Therefore, care must
be taken when investigating disease samples and when comparing them to control samples.
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Table 1. 1 VOCs, as “odor fingerprint”, could be emitted from different types of biological samples of human body.
Study Results
The
Published
Disease
origins
Method
Sample Size
# of
Paper
Detection
How reliable?
of odor
VOCs
Tissue tests: 100%
sensitivity and 95%
Ovarian
specificity.
Horvath et al.11
Trained dogs
N/A
N/A
Blood
cancer
blood tests: 100%
sensitivity and 98%
specificity
Lower level VOCs
Colorectal
16 cancer patients and
Wang et al.12
SPME-GC-MS
4
(p<0.01): Higher level
cancer
20 healthy controls
VOCs (p<0.05):
60
cancer
patients
and
100% sensitivity and
Breath
Phillips et al.17 Lung cancer GC-MS
22
48 non-cancer controls
81.3% specificity
Sensors
based
on
gold
Peng et al.18
Lung cancer
N/A
42
Accuracy >86%
nanoparticles
AUC 0.76
Prostate
59 cancer patients and
Khalid et al.21
SPME-GC-MS
4
Accuracy as high
Urine
Cancer
43 non-cancer controls
as 74%
Monteiro et
Renal cell
GC-MS
N/A
N/A
N/A
al.22
carcinoma
70% overall accuracy;
bladder
30 cancer patients and
23
Weber et al.
Gas sensor
N/A
70% sensitivity and 70%
cancer
59 non-cancer controls
specificity
Calderón41 cancer patients and
specificity/sensitivity
Santiago et
Lung cancer LC-MS
16
Sweat
55
non-cancer
controls
pair (80 and 79 %
al.24
Ion flow tube mass
31 high risk patients
Accuracy 75% with 78%
Colorectal
28
Batty et al.
spectrometry (SIFTand 31 low risk or non- N/A
specificity and 72%
Feces
cancer
MS)
cancer controls
sensitivity
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1.2

Extraction and Detection of VOCs as potential method for disease diagnosis

1)

VOCs Extraction
Since the low concentration of VOCs present in biological samples of human body, the

extraction and pre-concentration are crucial for the analysis of VOCs of interest29 and may affect
the reliability and accuracy of the analysis30.
To increase the reproducibility, selectivity, and extraction capacity and simplify the sample
preparation steps, solid-phase mirco-extraction (SPME) was developed to facilitate the rapid
sample preparation31. SPME is an extraction technique (
Figure 1. 2), in which a fine bare fused silica fiber or a fine silica fiber coated with a thin
layer of a selective coating (can be solid or liquid) is used to extract organic compounds directly
from aqueous samples for instrumental analysis by GC or GC-MS32. There are two types of
extraction based on the different samples: 1) the direct immersion SPME extracts VOCs by
immersing the fiber in liquid samples, and 2) the headspace SPME by suspending fiber in
headspace above the liquid phase. The analytes are firstly adsorbed during extraction on the surface
of the fiber materials as a result of chemical bonding, and then absorbed as being dissolved into
coating materials33. Four types of polymers are widely used as the coating materials,
polydimethylsiloxane (PDMS), divinylbenzene (DVB), polyacrylate (PA), and polyethyleneglycol
(PEG). Those materials could also be used through the combination blended with carboxen
(CAR)34. After pre-concentrating, the fiber with analytes trapped on its coating materials is
injected to the instruments and release analytes through thermal desorption. Deng et al.13
developed a simple, rapid and sensitive SPME/GC-MS method for the investigation of volatile
biomarkers in lung cancer blood. Poli et al.30 evaluated the potential of aldehydes from exhaled
breath in the diagnosis of non-small cell lung cancer by means of SPME/GC-MS with 93%
accuracy and precision between 7.2-15.1%. Monteiro et al.22 studied the volatile human urinary
metabolome difference of RCC and healthy individuals through the headspace SPME sampling
8

coupled with gas chromatography-ion trap/mass spectrometry (GC-IT/MS).

Wang et al.12

analyzed the VOCs in the blood samples from colorectal cancer patients and healthy controls with
headspace SPME sampling. Khalid et al.21 also applied SPME in headspace of urine samples to
identify the specific urinary VOCs for the detection of prostate cancer.

Figure 1. 2 The use of solid phase micro-extraction-gas chromatography-mass spectrometry
(SPME-GC-MS) (Source: Kamila Schmidt and Ian Podmore, 2015. Copyright © 2015 The
Journal of Biomarkers.29)
Similar to the theory of SPME, another novel approach for sample enrichment is referred
as stir bar sorptive extraction (SBSE), reported by Baltussen et al.35. Similar to SPME, SBSE uses
stir bars coated with the sorbent PDMS. The results of experiments conducted Baltussen et al.
indicated that the stir bars coated with PDMS present higher efficiency than SPME in the preconcentration of analytes from aqueous samples, with up to a 500-fold increase in sensitivity when
stirring between 30 to 60 min. The high efficiency could be contributed to the increased amount
9

of PDMS coated on the stir bars. Furthermore, the volatile compounds can also be easily and
conveniently handled due to the absence of drying step. Therefore, SBSE can be applied in the
analysis of VOCs in different types of aqueous samples, as well as the biological fluids. Melo et
al.36 carried out an analysis of antidepressants in plasma samples using SBSE and liquid
chromatography (LC) with high extraction efficiency. Soini et al.37 proved the high reproducibility
of SBSE in quantitative comparisons of the urinary profiles with relative standard deviations
(RSD) of 1-5% for a wide range of compounds. In one of our studies, SBSE was successfully
applied in identifying the specific urinary volatile organic compounds for the diagnosis of prostate
cancer.38 In addition, the coated stir bar could also be used as headspace sorptive extraction
(HSSE).39,40

Figure 1. 3 The set-ups of SBSE and HSSE. (Source: Ochiai et al., 2001. Copyright © 2001 The
Royal Society of Chemistry.40)

Other less common extraction techniques, such as purge and trap41, single drop microextraction42, etc. were also applied in VOCs extraction.
10

2)

VOCs Detection
VOCs are easy to be detected by using analytic instruments, like GC-MS, proton transfer

reaction-mass spectrometry (PTR-MS), selected ion flow tube-mass spectrometry (SIFTMS) or
gas sensors.21,29,43-45
As one of the most commonly used analytical technique, GC-MS is widely used in the
investigation of potential VOC cancer biomarkers based on its sensitivity and reliability in analyte
identification.12,13,22,30,38 It was shown that GC-MS can reach the ppb and low ppt levels in VOC
analysis with the pre-concentration steps.46,47 Fuchs et al.46 analyzed the breath gas aldehydes from
lung cancer patients using GC-MS. The concentrations in their study ranged from 7 pmol/l (161
pptV) for butanal to 71 nmol/l (1,582 ppbV) for formaldehyde.

In another study using GC-MS

conducted by Ligor et al.47, the limit of detection was in the range of 0.05 to 15.00 ppb. Meanwhile,
it provides the most detailed information of VOCs profiles and identifies analytes with most
certainty. However, GC-MS instruments are often expensive. Compared to GC-MS, PTR-MS and
SIFT-MS do not require a pre-concentration step and can work in real time, which make these two
better instant quantification techniques for VOCs analysis.48,49 Wehinger et al.48 identified ions at
m/z 31 and 43 from the exhaled breath that can best discriminate the primary lung cancer patients
and controls using PTR-MS. As mentioned in this study, even though the technique is simple and
time-saving for larger clinical evaluation, it is not possible for PTR-MS to differentiate between
compounds with the same molecular mass.
Some other detection techniques are also used in the analysis VOCs emitted from human,
such as ion mobility spectrometry (IMS)50. Compared with GC-MS, IMS gives a tenfold higher
detection rate of VOCs (500 seconds for IMS vs. 1h for GC-MS per sample). In one study of
detecting VOCs in exhaled breath of patients with lung cancer, the IMS was used by Westhoff et
al.50 and a combination of 23 peak regions were identified to discriminate the cancer patients and
controls without error.
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In addition, several types of electronic noses have been used in the studies of VOCs in
cancer.18,23,51 Natale et al.51 investigated the possibility of using electronic nose to identify the lung
cancer patients from controls. The results in their study indicated a 100% of classification of lung
cancer affected patients and 94% of controls. These sensors used in this study showed a good
sensitivity towards the compounds identified previously as potential lung cancer markers.
However, electronic noses are designed to recognize the VOCs found in established studies but
not to identify any unknown VOC patterns. Compared to the mass spectrometry based techniques,
the electronic nose is less time consuming and enables the potential of cheap, rapid, simple, and
miniature detection devices52,53. However, electronic noses are sensitive to moisture, less sensitive,
and with poor reproducibility.54,55 Additionally, electronic noses can only allow the semiquantitative detection of VOCs56.

1.3

VOCs and Urological Cancers
Cancer is a leading cause of death and disability globally, impacting more than 14 million

people each year.57 Urological cancers, such as prostate cancer (PCa), renal cancer (RCa), and
bladder cancer (BCa), are a major cause of morbidity and mortality worldwide. 58 In 2018, about
164,690 new cases of PCa, 65,340 of RCa, 81,190 of BCa and about 29,430 deaths in PCa, 14,970
in RCa, 17,240 in BCa are estimated in United States according to the American Cancer Society.59
In the United States, PCa is the most common cancer and the third leading cause of death in men.
About 1 in 7 men will be diagnosed with PCa during his lifetime.59 RCa and BCa also account for
more than 2% and 4% of cancer mortality in the United States.59
Diagnosis and treatment for each these urological cancers is associated with different, but
overlapping, clinical challenges.58 High-throughput genomic screening, proteomic profiling, and
metabolomics analysis of related functional protein molecules provide a large amount of
informational data and overview of clinical changes of cancer development and progression. The
cells, proteins, and metabolites in urine originated from kidney, prostate, and bladder could provide
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research information for biomarkers searching, such as genomics, proteomics, and
metabolomics.60-62 Urine, as a source of excretion from the urological system, is an ideal body
fluid for the investigation and detection of biomarkers for those urological cancers. Moreover,
urine can be easily sampled and non-invasive.
As early diagnosis and treatment of those urological cancers will improve the quality of
care and reduce mortality, there is a high demand of reliable, quick and patient-friendly diagnostic
method for cancers screening. As aforementioned, several studies have demonstrated that sniffer
dogs can differentiate cancer patients from controls by sniffing their urine.7-10 Cornu et al.8
reported the trained dog detected PCa by smelling urine with 91% for both sensitivity and
specificity. The study from Willis et al.10 provided further evidence that volatile compounds found
in urine can be identified by trained dogs with 73% sensitivity and 92% specificity. Additionally,
VOCs are easy to be detected by using analytic instruments, like gas chromatography-mass
spectrometry (GC-MS), or further developed gas sensors.21,43-45 All of those proved VOCs,
particularly in urine, as a desirable disease markers for its non-invasiveness, non-injury, easy
detection, high sensitivity and high specificity.

As one of the most promising metabolomics

approaches in cancer detection, the analysis of VOCs can potentially serve as a safe, non-invasive,
and specific test for the early detection of those urological cancers.

1.3.1 VOCs in Prostate Cancer
Currently, PCa are screened by the prostate-specific antigen (PSA) blood test and/or the
digital rectal exam (DRE). If the PCa is suspected based on the results of screening tests or other
symptoms, further tests, including trans-rectal ultrasound (TRUS) prostate biopsy will be required
to confirm the diagnosis.63 Furthermore, techniques used in advanced stages, such as bone scans,
computed tomography (CT) scan, and magnetic resonance imaging (MRI), may involve X-rays,
magnetic fields, sound waves and radioactive substances which can lead to the second injury of
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cancer patients.63 Diagnostic methods which can reduce stress and be more patient-friendly are
needed.
Currently, the gold standard for PCa screening is PSA. Adding to the fact that PSA is not
cancer specific, there is no reliable PSA threshold that can accurately distinguish men with or
without cancer.64

Therefore, anyone suspected of PCa must undergo prostate biopsy. Depending

on the PSA level, up to 80% of men

were found no cancer based on their biopsy results. 65

Therefore, there is a significant interest in finding a more accurate PCa-specific biomarker. Khalid
et al.21 showed the discrimination power of urinary VOCs profile in differentiating PCa patients
from controls with 71% accuracy based on only 4 VOCs. In one of our studies38, the performance
of VOCs has been tested and validated with AUC 0.92 (96% sensitivity and 80% specificity). The
VOCs based prostate cancer diagnosis tool would be promising in future clinical use.
Several biomarkers have been developed to improve upon the limitations of serum PSA
including Iso-PSA, prostate cancer antigen 3 (PCA3), 4Kscore, Prostate Health Index (PHI),
TMPRSS2:ERG and ConfirmMDx.66-71 Among those markers, IsoPSA, PHI and 4Kscore are all
PSA-based assay for PCa risk assessment.66,69,71 PCA3 is a noncoding RNA that is prostate specific
and highly overexpressed in prostate cancer.72 TMPRSS2-ERG gene fusions are reported to be the
predominant molecular subtype of prostate cancer.73 ConfimMDx is an epigenetic test for PCa
diagnosis before prostate biopsy.70 Again, these methods are not able to provide satisfactory
screening capability for PCa.

1.3.2 VOCs in Renal Cancer
The most common type of kidney cancer is renal cell carcinoma (RCC) consisting about
90% of kidney cancer cases. RCC is a heterogeneous malignancy, both morphologically and
genetically, which is classified into different histologic subtypes, including clear cell RCC (most
common one), papillary RCC, chromophobe RCC and other less common subtypes.74-76 The
outcome of RCC is usually unpredictable even after a long period of asymptomatically
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development and progression.77 Therefore, its diagnosis is often incidental through the use of
medical imagology and is frequently detected at an advanced stage and metastatic when detected
clinically.78 Additionally, RCC is particularly challenging to treat because of its relative
insensitivity to radiotherapy and conventional chemotherapy drugs.79 The early screening of RCC
could improve the outcome of diagnosis. However, no early screening method is recommended to
screen for kidney cancer clinically in people at average risk or increasing risk.
The potential of urinary VOCs used in RCC diagnose has been highlighted in previous
studies.22,80,81 The purpose of most previous studies were focused on the searching of specific
VOCs in RCC patients without further validation.22,80 In the study reported by Marica Monteiro in
201781, the selected VOCs was validated in different patients group besides the searching of
specific VOCs, but the performance of VOCs in differentiating RCC patients and controls was not
determined. Besides, two urinary exosomal proteins, AQP-1 and PLIN2 have shown promise as
the biomarkers in RCC diagnosis.82 It should be noted that AQP-1 and PLIN2 can be found in
clear cell and papillary RCC but not in the chromophobe subtype of RCC. However, VOCs based
screening has great potential to be developed as a more universal screening tool of almost all types
of RCC or even specific screening tool for each type of RCC because of the metabolic distinction
shown with each selected VOC between cancer patients and controls, Unlike the ELISA detection
methods of AQP-1 and PLIN2, the VOCs based diagnostic model could be developed as a high
throughput and fast screening method in clinic enabled by high performance GC/MS and statistic
assistance.

1.3.3 VOCs in Bladder Cancer
Bladder cancer (BCa) is the second most common genitourinary malignant disease in
United States.83 And it is also a heterogeneous malignancy, with different histologic subtypes,
including transitional cell carcinomas (90%), squamous cell carcinomas (5%), and
adenocarcinomas (less than 2%).84 The most common symptom of BCa (in 80%-90% of the
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patients)85 is hematuria, or blood in the urine, and others including complaints of dysuria (painful
urination), increased frequency or urgency of urination, failed attempts to urinate, a mass in the
bladder or a ureteral obstruction.86,87 Intravenous pyelography, cystoscopy, transurethral biopsy,
and imaging techniques, such as magnetic resonance imaging and computerized tomography scan,
are always involved in the clinical diagnosis procedures of potential BCa.87,88 On the other hand,
no early screening method for bladder cancer is recommended in United States. 89
Many studies are attempting to identify genetic and chemical markers in order to
complement the use of clinical features and better assess the risk level of BCa.90,91 The
overexpression of the p53 gene, cells containing multiple aneuploid cell lines, and the expression
of the Lewis‐ x blood group antigen were found to be the markers of high risk BCa.90 Furthermore,
nuclear matrix protein 22 (NMP22) and bladder tumour antigen (BTAstat) are more sensitive (50–
85% and 50–70%), but less specific (60-70%), than urine cytology, which have been approved by
FDA as protein markers of bladder cancer.23,92
Recently, VOCs are also suggested in different studies that have potential in differentiating
patients of BCa from controls. And according to Weber et al.23, the best diagnostic performance
they obtained through the comparison between healthy volunteers and bladder cancer patients was
70% overall accuracy (70% sensitivity and 70% specificity) using a gas sensor array and pattern
recognition. The results of another study using gas sensors, reported from Khalid et al.93, also
showed potential of VOCs for the diagnosis of bladder cancer (the best performance: 100%
sensitivity and 94.6% specificity). All those studies have revealed the potential of VOCs used in
bladder cancer diagnosis.

1.4

Potential molecules pathways related to VOCs profile for cancer direction

1.4.1 Androgen signaling and one-carbon metabolism
The androgen receptor (AR), is a nuclear receptor that is activated by binding either of the
androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating
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into the nucleus.94,95 It plays an essential and important role in PCa initiation, progression, and
metabolic adaptation that takes place during PCa progression. As a transcription factor, the AR
directly affects essential catabolic and biosynthetic pathways through modulating the expression
of related effectors and regulators. On the other hand, the AR, as a modulator of the one-carbon
metabolism, can also affect epigenetic processes, DNA metabolism, and redox balance indirectly,
which are all important factors in tumorigenesis.96
One-carbon metabolism involves a complex network with two central cycles: (1) the folate
cycle and (2) the methionine cycle. One-carbon metabolism also regulates essential processes
including DNA synthesis and repair, epigenetic methylation reactions, redox homeostasis, and
protein synthesis. The balanced flux through these four pathways, e.g. folate cycle, methionine
cycle, transsulfuration pathway, and polyamine synthesis, is essential for cellular homeostasis.
(Figure 1. 4 Part A),96 and disruptions of the balanced flux could contribute to the pathogenesis of
many diseases, including cancer.97 Cancer creates a demand and dependency on one-carbon
metabolism. For example, methyl group availability for methyltransferases that modulate gene
expression via epigenetic mechanisms is inﬂuenced by ﬂux within the folate cycle and methionine
cycles.98,99 Alterations in one-carbon metabolism may contribute to tumorigenesis through fueling
DNA synthesis, changing the DNA and histone methylomes, promoting protein translation,
driving cell cycle progression, and modulating redox balance. These changes can in turn promote
sustained proliferation, induce tumorigenic gene expression changes, contribute to genomic
instability, and promote survival—all important processes in tumorigenesis and cancer
progression.96
The progression and metastasis of tumors were associated with metabolite increases in
glutathione and cysteine/methionine metabolism pathways. For example, clear cell RCC is
characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and
antioxidant response, reported by Hakimi et al..100 Bridging the gap between the Cancer Genome
Atlas (TCGA) transcriptomic profiling and the metabolomic data in their studies, the authors were
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able to integrate the pathway-level metabolic atlas and to demonstrate discordance between
transcriptome and metabolome.
Studies in PCa cell lines demonstrate AR-regulation of one-carbon metabolism enzymes,
and altered cellular methylation potential in response to androgens.101-104 For example, sarcosine,
a methylated metabolite of the one-carbon pathway, was found be accumulated in PCa clinical
samples.102 In the prostate, androgens and the AR regulate the activity and/or expression of several
enzymes involved in the one-carbon metabolism pathways, specifically enzymes involved in Sadenosyl-methionine (SAM) homeostasis and the entry into the transsulfuration and polyamine
synthesis pathways (Figure 1. 4 Part A). Studies directed to identify AR transcriptional networks
in different models of PCa have demonstrated an involvement of the AR in global metabolism by
directly targeting enzymes involved in several metabolic processes.105-108 These findings illustrate
the role of the AR in PCa tumorigenesis by controlling metabolism, and the value of integrating
metabolomic profiling and gene expression analysis for the identification of new biomarkers and
therapeutic targets. Also, these observations emphasize the link between the AR and one-carbon
metabolism, and the potential effects that changes in AR signaling, that can occur with disease
progression, may have on essential cellular processes.

1.4.2 The effect of Metabolic phenotype on fatty acid and phospholipid synthesis
The zinc accumulating and citrate synthesizing phenotype is the hallmark of the healthy
prostate epithelial cell.109,110 However, PCa cells reverse this phenotype and adopt a zinc wasting,
citrate oxidizing phenotype, thereby representing a major shift in energy metabolism.111 This shift
allows these cells to utilize the Krebs cycle and subsequent oxidative phosphorylation (Figure 1.
4 Part C). It has long been identified that PCa cells do not conform to the standard Warburg effect
seen in most cancers, which described in the early to mid-1900s by Otto Warburg.112

Malignant

cells shift their dominant ATP producing pathway away from oxidative phosphorylation to aerobic
glycolysis.112 Unlike most cancer cells that resort to aerobic glycolysis, prostate cancer cells
exhibit a higher level of citric acid cycle activity compared to benign cells.110
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The increased

activity of citric acid cycle, essential for the progression of malignancy, was induced by the
inability of malignant prostate cells to accumulate high zinc levels, which inhibits citrate
oxidation.113
Another metabolic hallmark of many cancer cells is the enhanced lipogenesis, arising from
increased activities of fatty acid biosynthetic enzymes.114-116 Clear cell RCC (ccRCC) is
histologically defined by its lipid and glycogen-rich cytoplasmic deposits.117,118 In the study of Du
et al.118, the lipid deposition of ccRCC was investigated with focus on the carnitine
palmitoyltransferase 1A (CPT1A), as a direct HIF target gene.

Prostate cancer cells often utilize

lipids derived from androgens through the expression of the AR.119 However, these cells can also
utilize de novo lipid synthesis to produce fatty acids in order to obtain energy. This shift to a lipidproducing phenotype is a key turning point in the progression of prostate cancer. The de novo lipid
producers have ability to produce the key energetic molecules for growth without the regulation
of androgens (Figure 1. 4 Part C).120 Clinically, this is problematic as it represents a disease that is
unresponsive to androgen deprivation therapy, known as castration-resistant prostate cancer.121.
These producers include fatty acid synthase (FASN), sterol regulatory element binding protein 1
(SREBP1), and steroyl CoA desaturase. Among them, the enzyme FASN functions to help
synthesize long-chain fatty acids. It is believed that unregulated FASN activity within prostate
tissue is the beginning of malignant phenotype, and has been argued to be necessary for PCa
growth maintenance.122 The use of lipid by the PCa cells illustrates that these cells bypass potential
degenerative pathways, and rather utilize the anabolic pathways in order to maintain energy and
growth.123 A variety of fatty acid moiety were detected in our preliminary study and that supports
the importance of specific VOCs in PCa.
Additionally, phospholipids, also as the downstream products of enhanced lipogenesis, in
the cancer cell membrane have been found to be abnormal compared with normal cells. The plasma
membrane of normal cells is characterized by an asymmetric distribution of various phospholipids
over two membrane leaflet. Phosphatidylethanolamine (PE) resides in the inner leaflet facing the
cytosol (Figure 1. 4 Part C). The disrupted membrane asymmetry of cancer cell exposes PE to
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extracellular space, which can serve as a molecular target for anticancer therapy.124 The increasing
need of PE in cancer cell may correlate the excessive consumption of ethanolamine (mostly appear
in control group of our preliminary study) and enhanced lipogenesis.
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Figure 1. 4 A comprehensive illustration of Androgen signaling, one-carbon metabolism, and metabolic phenotype. Part A.
One-carbon metabolism involves a complex network with four pathways: (1) folate cycle; (2) methionine cycle; (3) transsulfuration
pathway; (4) sarcosine pathway. In the prostate, androgens and the AR regulate the activity/expression of several enzymes involved in
the one-carbon metabolism pathway. Enzyme abbreviations are as follows: SARDH: Sarcosine Dehydrogenase; SHMT: Serine
hydroxymethyltransferase; GNMT: Glycine-N-methyltransferase; MTHFR: Methylene tetrahydrofolate reductase; MAT: Methionine
adenosyltransferase; AHCY: S-adenosylhomocysteine hydrolase; CBS: Cystathionine beta-synthase; CTH: cystathione gamma-lyase
or gamma-cystathionase. Part B. Hypothetical cycle of metabolism involving glycine, serine, ethanolamine, choline, and betaine.101
Part C. Enhanced lipogenesis, arising from increased activities of fatty acid biosynthetic enzymes (including ACC1, FASN, and
stearoyl CoA desaturase (SCD1)), is a metabolic hallmark of many cancer cells.106-108 In addition, the plasma membrane of normal
cells is characterized by an asymmetric distribution of various phospholipids over two membrane leaflet. PE resides in the inner leaflet
facing the cytosol. The disrupted membrane asymmetry of cancer cell exposes PE to extracellular space. Furthermore, PE is also
highly exposed on endothelium cells in tumor vasculature. PA, phosphatidic acid; PC, phosphatidylcholine; DAG, diacylglycerol;
CDP-ethanolamine, Cytidine diphosphate ethanolamine.
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1.5

Research Objectives
The overarching goal of this research was to develop and validate the urinary VOCs based

diagnostic tool for prostate cancer and renal cancer for early screening and even the risk
stratification. Specific objectives of the project are described as follows.
1)

Develop and validate a urinary VOCs based model for prostate cancer diagnosis.
Identify specific VOCs in urine that can differentiate prostate cancer patients from controls.

The urinary VOCs based PCa diagnostic model would be validated through training-testing set.
Evaluate the model with external cohort of patients to verify the performance of the VOCs based
diagnostic model in differentiating PCa patients from controls.
2)

Develop and validate a urinary VOCs based model for prostate cancer risk assessment.
Examine specific urinary VOCs in PCa risk assessment. The urinary VOCs profile were

compared between PCa low risk group and PCa high/intermediate group. A risk predictive
modeling using logistic regression and cross-validation were developed and assessed.
3)

Apply the VOCs tool for other cancer early detection study. Develop and validate a urinary

VOCs based model for clear cell renal cell carcinoma diagnosis.
Screen the specific urinary VOCs for ccRCC early detection. The urinary VOCs based
ccRCC diagnostic model was validated through training-test set. The performance of those
selected VOCs were evaluated again through the external cohort of ccRCC patients.
4)

Testing the specificity of the two VOCs models by cross examining the discrimination

power of VOCs in prostate cancer and clear cell renal carcinoma. The performance of developed
urinary VOCs based PCa and ccRCC diagnostic models in cohorts of patients with increased
complexity would be tested.
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Chapter 2: Application of Urinary Volatile Organic Compounds (VOCs) for the diagnosis
of Prostate Cancer

Reproduced in part with permission from the Genitourinary Cancer.


Parts of this chapter were published in Genitourinary Cancer as a research article in 2019.
(Qin Gao, Xiaogang Su, Michael Hani Annabi, Brielle R Schreiter, Thomas Prince,
Andrew Ackerman, Sara Morgas, Valerie Mata, Heinric Williams,*, Wen-Yee Lee,*.
Genitourinary Cancer, 2019)



This chapter introduces a study to address the critical and unmet need for a simple,
effective, and sensitive diagnostic tool for prostate cancer. We collected urine samples
from 108 biopsy proven prostate cancer positive and negative patients to develop a
metabolomics based model to detect prostate cancer. The model was validated and showed
high discriminating power in prostate cancer detection.
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Abstract:
Background: Prostate cancer (PCa) screening using serum prostate specific antigen (PSA) testing
has caused unnecessary biopsies and over-diagnosis due to its low accuracy and reliability.
Therefore, there is an increased interest in identifying better PCa biomarkers. Studies showed
that trained dogs can discriminate PCa patients from unaffected men by sniffing urine. We
hypothesized that urinary volatile organic compounds (VOCs) may be the source of that odor and
could be used to develop urinary VOC PCa diagnosis models.
Methods: Urine samples from 55 and 53 biopsy proven PCa positive and negative patients
respectively were initially obtained for diagnostic model development. Urinary metabolites were
analyzed by Gas Chromatography-Mass Spectrometry. A PCa diagnosis model was developed and
validated using innovative statistical machine-learning techniques. A second set of samples (53
PCa positive and 22 negative patients) were used to evaluate of were used to evaluate the
previously developed PCa diagnosis model.
Results: The analysis resulted in 254 and 282 VOCs for their significant association (p<0.05) with
either PCa positive or negative samples respectively. Regularized logistic regression analysis
and the Firth method were then applied to predict PCa prevalence, resulting in a final model that
contains 11 VOCs. Under cross-validation, the area under the receiver operating characteristic
curve (AUC) for the final model was 0.92 (sensitivity: 0.96; specificity: 0.80). Further evaluation
of the developed model using a testing cohort yielded an AUC of 0.86. As a comparison, the PSAbased diagnosis model only rendered an AUC of 0.54.
Conclusion: The study describes the development of a urinary VOC-based model for PCa
detection.
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Clinical Practice Points
•

Due to the low specificity of current prostate cancer screening with serum Prostate-Specific

Antigen (PSA), up to 80% of men who are found to have elevated PSA value and subsequently
undergo prostate biopsies will either not be diagnosed with prostate cancer (PCa) or be diagnosed
with an indolent form of PCa, which is unlikely to cause significant morbidity or mortality. It is
urgent to address the problem of over-diagnosis and overtreatment in prostate cancer care.
•

We developed urinary metabolites (i.e. VOCs) based model to detect PCa with a higher

accuracy (87%) than PSA alone (59%) in PCa screening, thus potentially providing a better
alternative than current PSA test to accurately and reliably diagnose prostate cancer.
•

As a non-invasive and sensitive tool, the VOC model is ideally suited for early diagnosis

of PCa. Future validation of our model will enable clinically relevant and cost-effective, point-ofcare PCa screening and prognosis with the potential to save health care costs.

2.1

Introduction
In United States, prostate cancer (PCa) is the most common non-cutaneous cancer and the

second leading cause of cancer death in men 59. Serum prostate specific antigen (PSA) is the most
commonly used biomarker for PCa. However, PSA lacks accuracy for PCa diagnosis and, as a
result, contributes to unnecessary prostate biopsies, over-diagnosis and over-treatment of the
disease 64. Therefore, finding more sensitive and reliable PCa screening methods is greatly needed.
In United States, approximately 19 million men undergo serum Prostate-Specific Antigen
(PSA) blood testing annually 125, resulting in 4.7 million abnormal PSA test results (≥4.0 ng/mL)
leading to 1.3 million biopsy procedures 126 . Only 22% of men undergoing their first biopsy will
be diagnosed with PCa 127. In addition, more than a third of the men with PCa on prostate biopsy
will have clinically indolent or low-risk disease. Thus, a better screening assay that detects
clinically significant PCa could potentially eliminate nearly 80% (~1 million) prostate biopsies,

98

avoiding the unnecessary expense and the associated risks of pain, infection, bleeding, difficulty
urinating and anxiety

128

. Therefore, developing an effective diagnostic test capable of not only

identifying men with PCa, but more importantly, those with clinically significant disease is needed.
Metabolic reprogramming is a well-recognized hallmark of cancer and metabolomic
approaches have shown promise in oncology diagnosis, prognostic and treatment
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. Studies

reported that trained animals can detect cancers by “sniffing” the urine from patients with breast
130

, bladder 131, prostate 8,132, colorectal 133, and lung cancer 134. In PCa studies, trained dogs were

able to discriminate between patients with and without disease (sensitivity and specificity >90%)
8

. Since the odor of urine perceived by the dogs is produced by volatile organic compounds

(VOCs), gas chromatography-mass spectrometry (GC/MS) has been proposed to detect VOCs in
men for PCa.
In general, VOCs can be produced from the human body and released through breath,
blood, skin, urine and feces
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. As these VOCs are thought to reflect the physiological and

metabolic status of the individual 5, they could represent tumor biology and response to therapy in
individuals with cancer 5. In addition, VOCs can be conveniently and reliably detected by Gas
Chromatography and Mass Spectrometry (GC-MS), or gas sensors 21,44, which highlights the easy
translatability of this application if successful. Taken together, the results of the previous studies
coupled with the versality of VOC detection using GC-MS provided the framework to
systematically study urinary VOCs as potentially biomarkers for PCa diagnosis. The model was
developed and evaluated with the aid of statistical machine learning techniques and its
performance was compared to the current standard, i.e., the PSA test.

2.2

Experimental section

2.2.1 Chemicals and Materials
All chemicals were of analytical grade. Mirex (99.0%, Dr. Ehrenstorfer GmbH, Germany),
used as the internal standard, was purchased from the Laboratories of Dr. Ehrenstorfer, Germany.
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Mirex solution of 100 mgL-1 was prepared in methanol (LCMS grade, Burdick & Jackson
(Muskegon, MI, USA)). Hydrochloric acid (HCl, 37%) was purchased from Sigma–Aldrich (St.
Louis, MO, USA). Ultra-pure deionized water from Milli-Q system (Millipore, Bedford, MA,
USA) was used in the preparation of HCl solution and dilution of urine samples.
2.2.2 Patient recruitment and sample collection
Internal Review Board approvals and written informed consents were obtained for the
multi-institutional study.

Patients presenting to Geisinger Medical Center urologic clinic for

evaluation of elevated PSA >2.5 ng/ml or abnormal digital rectal exam in the urology clinic were
selected for the study. Patients who did not wish to participate in this study or whose urinalysis
was suspicious for infection were excluded. All patients provided urine specimens for dipstick
urinalysis to rule out infection prior to office-based transrectal ultrasound guided prostate biopsy
by a single provider (HW). The remaining urine samples (50 ml) were collected and stored at 80oC prior to VOC analysis. Patients with a positive PCa diagnosis represented the cancer cases.
Those with benign prostate or low volume (≤2 of 13 cores involved) high grade prostate
intraepithelial neoplasia or atypical small acinar proliferation (ASAP) were included in the control
group so as to mimic the real world clinical scenario.
had a negative repeat 6 month prostate biopsy.
testing.

The two patients with low volume ASAP

The study consisted of two cohorts: training and

In the training cohort, 108 men (aged from 40 to 84) were included (
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Table 2. 1). Of the 108 men, 55 were diagnosed with PCa, while 53 were negative for PCa
(herein, called controls).

To validate the developed PCa diagnostic model, urine specimens from

53 PCa positive and 22 PCa negative patients (herein, called testing cohort) were obtained from
an internist (MHA) with the Clinic Internal Medicine of El Paso, Texas. Specimens were obtained
prior to patient referral to urology. Patients were subdivided into their respective groups based on
prostate biopsy results as described for the training group
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Table 2. 1 Demographic information of prostate cancer and cancer-negative patients in the VOC PCa diagnosis model development.
Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables.

Training Cohort (Model Development)

PSAa

N
(ng/mL)

Gleason score
6
7
8
9

Prostate cancer
patients

Controls

55
5.29 (0.08-1987)

53
2.6 (0.1-18.2)

Testing Cohort (Model Evaluation)

p value b

0.28

Prostate cancer
patients

Controls

p value b

53
3.75 (0.08-75)

22
5.21 (1.8-20)

0.96

N/A

N/A

20 (36%)
23 (42%)
6 (11%)
6 (11%)

31 (58%)
16 (30%)
3 (6%)
3 (6%)

a

PSA: prostate specific antigen;

b

The p value from the t-test of the PSA numbers between prostate cancer and control groups
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2.2.3 Extraction of VOCs from urine samples by Stir Bar Sorptive Extraction (SBSE)
Urine samples were thawed in ice, transferred to centrifuge tubes, and centrifuged for 10
minutes at 300g prior to extraction. To extract the organic metabolites (i.e. VOCs), 1.0 mL of urine
sample supernatant, 19.0 mL of DI water, 300 µL of 100 ppm Mirex solution (internal standard)
and 600 µL of 2 M hydrochloric acid were added into a 20 mL amber vial. A commercially
available Stir Bar coated with polydimethylsiloxane (Twister™, 10 mm × 1 mm, Gerstel, Mülheim
an der Ruhr, Germany) was then placed into the vial, and the solution was stirred for 2 hours at
1000 rpm. At the end of the stirring, the stir bar was removed from the solution, rinsed with DI
water, dried with lint free paper, and placed into a thermal desorption tube for chemical analysis.
2.2.4 GC-MS analysis
Urinary VOCs were analyzed in a thermal desorption unit (TDU, Gerstel), coupled with a
6890 GC system and a 5973 N Mass Selective Detector (Agilent Technologies, Wilmington DE).
The thermal desorption process was programmed as follows. The initial temperature was set at 45
°C holding for 0.5 min; the temperature was increased to 300 °C at 60 °C min-1 and held for 5 min.
Desorption gas flow was set at 1.0 mL min-1. During desorption, all the desorbed compounds were
concentrated in a cold injection system, CIS4 (Gerstel), at -40 °C prior to GC injection. Once the
desorption process was completed, the CIS4 was heated to 300 °C at 12 °C sec-1 and held for 5
min in a solvent vent mode. The VOCs were separated and analyzed by GC-MS using splitless
mode through a ZB-5ms capillary column (30m × 0.25mm × 0.25μm, Phenomenex, USA). The
oven temperature was programmed as follows: held at 35 °C for 5 min; heated to 300 °C at 10 °C
min-1, and held for 10 min. The VOCs were detected by Mass Selective detector in scan mode (20500 m/z). The National Institute of Standards and Technology (NIST) Library was used for the
identification of VOCs profile in urine sample.
2.2.5 Data processing and statistical analysis
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We used mirex as the internal standard because of its non-existence in human urine. The
relative intensity of each VOC peak could then be normalized against that of Mirex, allowing semiquantitative statistical analysis of VOCs.
Over 9,000 different VOC types were found in the urine samples, resulting in a highdimensional modeling problem. To streamline the analysis, we first removed the VOCs that could
be observed in less than 3% of the entire population. The remaining variables were screened by
testing the difference in each VOC between the PCa positive and control groups. The Wilcoxon
rank-sum test was used since it can accommodate the zero inflation among many VOCs. Heat
maps were generated to visualize those significant VOCs (p<0.05) in the PCa positive and control
groups.
Applying a liberal cutoff of 0.2 to the p-values, over 800 VOCs remained for the model
development. To deal with this p>>n scenario (i.e., numbers of VOCs are much greater than the
number of samples), we fit regularized logistic regression models 136 with LASSO 137 penalty, and
the 10-fold cross-validation was used to select the optimal tuning parameter. The final logistic
model was then evaluated via the Receiver Operating Characteristic (ROC) curve and other
performance measures on the basis of jackknife prediction

138

, which helps alleviate the over-

optimism induced by variable selection. Furthermore, Firth’s approach was taken to fit the final
logistic model in order to achieve bias-reduction for the small sample scenario and deal with the
nearly complete separation seen in the data 139. Another R package, known as OptimalCutpoints,
was used to determine the optimal cut point for the diagnostic model corresponding to the
maximum Youden Index 140. All statistical analyses are performed using the open-source statistical
computing software R 141.

2.3

Results
The study analyzed VOCs in urine samples collected from patients to develop the urine

metabolome based PCa diagnosis model. All VOCs were identified using an existing NIST library
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and significant VOCs were selected based on their occurrence and relative quantity in the urine.
One mL of urine sample was extracted by stir bar sorptive extraction (SBSE) , and the VOCs were
then analyzed by GC/MS. The quantity of each VOC was normalized to the internal standard,
mirex, by taking the ratio between the signal of the compound and that of mirex.
A total of 9,144 potential VOCs were detected in urine from 108 patients (55 PCa positive
and 53 PCa controls).

Using the Wilcoxon test, 254 VOCs were found to be positively related to

PCa and 282 VOCs were negatively associated at p<0.05 (Figure 2. 1 a).
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Figure 2. 1: a) The heat map of significant VOCs by Wilcoxon test (p <0.05) in PCa vs PCa
negative samples. The correlation between VOCs and patients ranges from low (red) to high
(blue); b) the heat map of 11 selected VOCs in the urinary VOCs based PCa diagnostic model.
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The values of those selected VOCs in patients show a strong pattern in distinguishing PCa
positive and negative patients.

To avoid missing important predictors for PCa prevalence, a relatively large
(with p<0.20) was applied to screen variables for further development of the regression
resulting in a total of 850 potential VOCs. After 𝑙1 regularization, the final logistic model
contains 11 VOCs (listed in the
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Table 2. 2), and a heat map was generated to show their differentiation in PCa positive and
negative patients (Figure 2. 1 b). On the basis of predicted probabilities from the final model
obtained via jackknife cross-validation, the area under the receiver operating characteristic (ROC)
curve (AUC) is 0.92 with sensitivity of 0.96 and a specificity of 0.80 respectively. As a comparison,
we also built a logistic model with PSA only, which yielded an AUC of 0.54. The model resulted
in a sensitivity at 0.60 and a specificity at 0.42 respectively when applied to the test data (Figure
2. 2 b). Testing the performance of the PCa diagnostic model using an external cohort of 75 patients
(53 PCa patients and 22 PCa negative patients) yielded a ROC curve of of 0.86 (Figure 2. 3), with
an 87% sensitivity and a 77% specificity.
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Table 2. 2. The VOCs selected by logistic regression models for prostate cancer diagnosis prediction and risk assessment.
CAS
Number1

Formula

000472-41-3

C18H20O2

000050-28-2
129086-73-3
1000215-252
1000126-505

C18H24O2
C16H32O3

000995-83-5
003555-47-3
020548-62-3
024535-53-3
075132-80-8
101100-38-3

C15H22O
C4H5N3O2
C10H32O4Si
5

C12H36O4Si
5

C26H42O4
C12H8ClN
O3S
C3H7Cl5N3
P3
C15H22O2

Chemical Name

Occurrence

Dominating
Group

p

PCa negative

value4

PCa(+)
2

PCa(-)3

1.29E-07

0

22

PCa negative
PCa negative

9.38E-05
4.64E-06

4
1

20
19

PCa negative

2.54E-05

0

15

2-amino-Imidazole-5-carboxylic acid

PCa negative

2.54E-05

0

15

1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane

PCa positive

1.21E-06

35

9

PCa positive

1.44E-06

52

37

PCa positive

0.000388

23

8

4-Nitro-4'-chlorodiphenylsulfoxide

PCa positive

8.06E-06

46

23

1-Propylpentachlorotriphosphazene

PCa positive

5.16E-06

47

36

2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6detetrahydrocyclohexanone

PCa positive

4.32E-05

23

4

4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4yl)-phenol
Estradiol
Ethyl à-hydroxymyristate trisiloxane
1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl2)propane

1,1,1,5,5,5-hexamethyl-3,3bis[(trimethylsilyl)oxy]-Trisiloxane
Phthalic acid, bis(7-methyloctyl) ester

1: Chemical Abstracts Service number
2: PCa(+): prostate cancer positive patients
3: PCa(-): prostate cancer negative patent
4: p value: the p value of selected compounds from Wilcoxon rank-sum test
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Figure 2. 2: a) The ROC curve for VOC PCa diagnosis logistic model verified in 108 patients;
b) The ROC curve for logistic model with PSA only.
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Figure 2. 3: The ROC curve for VOC PCa diagnosis logistic model tested in 75 patients
2.4

Discussion
There is significant interest in PCa biomarker development as evidenced by the number of

biomarkers currently available for disease diagnosis, risk stratification, prognosis and response to
treatment142. In this study, we developed a urinary VOCs based model for PCa diagnosis. The
analytical method allowed for an easy, fast and efficient analysis of VOCs without tedious sample
preparation. The solventless sample preparation technique preserved the sample integrity and
permitted effective analyses for processing large number of samples, which is an important factor
for clinical translatability. Unlike gas-sensors (e.g., E-nose) which are based on signal indications
44

, the GC-MS method identified relevant compounds which can be further validated or

interrogated in future metabolomics and physiological studies. Using the internal standard, Mirex,
facilitated the semi-quantitative determination of VOCs. The expression of VOCs as continuous
data rather than as binary provides a more disease-specific representation of metabolite
concentration (i.e increase or decrease) in vivo, and improves the subsequent model development.
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For the urinary VOC based PCa diagnostic model, 11 VOCs were selected into the final
logistic regression. The model was validated and produced an AUC of 0.92 (Figure 2. 2 a),
suggesting the potential of urinary VOCs for PCa diagnosis. While other studies have evaluated
various urinary analytic techniques for PCa detection, the study by Khalid et al represents the best
study to date, utilizing urinary VOCs for this purpose. Their study was comprised of 59 PCa
patients and 43 controls. Following urinary VOC analysis of prostate cancer positive and negative
specimens, they manually selected 4 VOCs (2,6-dimethyl-7-octen-2-ol, pentanal, 3-octanone, and
2-octanone) for their PCa detection model.

The accuracy of this model was 63-65% but

improved to 74% and 65% when combined with PSA using their random forest and linear
discriminant analysis methods respectively.

21

. In their study, PSA alone was marginally better

than the 4 VOC model which call into question the clinical utility of these set of biomarkers.

By

comparison, in our study, there was a significant difference between the performance of PSA
(AUC of 0.54) and the diagnostic model (AUC of 0.92). Manually selection of VOCs likely
introduced bias into the model as opposed to allowing the discriminatory analysis to dictate the
final VOCs that would come to define each cohort.

In our study, there was a blend of VOCs that

were increased or reduced in either PCa positive or PCa negative groups. In the Khalid study, the
same cohort was used for both discovery and validation. Despite using robust statistical methods
to minimize the bias associated with this approach, the sensitivity and specificity of the 4 VOC
remained poor.

In this study, in spite of using a rural Pennsylvania patient cohort to develop the

PCa detection model, the validity of the model was upheld when tested in an urban Texas
population with an AUC of 0.86 with sensitivity and specificity of 0.87 and 0.77 respectively.
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Table 2. 3. Comparison in sensitivity, specificity, and AUC from various biomarkers in prostate cancer diagnosis
Our study

Potential biomarkers

VOCs based model
PSA

Iso-PSA

PCA3

TMPRSS2
:ERG

Validation Evaluation
Sensitivity

0.96

0.87

0.60

0.90

0.68

0.24

specificity

0.80

0.77

0.42

0.48

0.58

0.93

AUC

0.92

0.86

0.54

0.79

0.68

0.59
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4Kscore

PHI

ConfirmMDx
0.68
0.64

0.82

0.68

Several other biomarkers, including Iso-PSA, prostate cancer antigen 3 (PCA3), 4Kscore,
Prostate Health Index (PHI), TMPRSS2:ERG and ConfirmMDx

66-71

alternatives to address the challenges of PSA test in PCa diagnosis.

, were developed as

Among those markers,

IsoPSA, PHI and 4Kscore are PSA-based assay for PCa risk assessment 66,69,71. PCA3 is reported
to be a noncoding RNA that is prostate specific and highly overexpressed in PCa

72

; and

TMPRSS2-ERG gene fusion is the predominant molecular subtype of PCa 73. ConfimMDx is an
epigenetic test for PCa diagnosis before prostate biopsy 70,143. However, these PCa diagnostic tests
are still limited by either their low sensitivity and/or low specificity (
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Table 2. 3). The metabolome can be considered as the amplified output of the biological
system, and therefore metabolomics profiling is emerging as a promising strategy for PCa
diagnosis 144. In this study, the VOCs metabolome based PCa diagnosis model outperformed those
aforementioned diagnostic PCa biomarkers (
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Table 2. 3).
Among the 11 compounds selected in the PCa diagnosis model, 5 showed higher levels in
the PCa negative group), while the remaining 6 were positively related with PCa. Some of these
compounds may be directly or indirectly involved in androgen receptor (AR) signaling. For
example, androgens and AR in prostate regulate the activity/expression of the enzymes involved
in lipogenesis 96. Lipogenesis is mediated by increased activities of fatty acid biosynthetic enzymes
(including ACC1, FASN, and stearoyl CoA desaturase (SCD1))

114-116

. The urinary fatty acids

and/or fatty acid metabolites found in this study could be a reflection of such activities and
therefore relevant in PCa.

Figure 2. 4. Chemical structures of four representative VOCs selected by the regression model
Ethyl α –hydroxymyristate (Figure 2. 4), was reduced in PCa patients.

Numerous

epidemiological studies suggest that myristic acid (MA) significantly increase the risk of prostate
cancer–specific mortality among patients diagnosed with localized disease 145,146.
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In vivo studies

in mice showed that myristoylation of Src kinase promoted Src-induced and high-fat diet–
accelerated prostate tumor progression147. The low levels of ethyl α-hydroxymyristate seen in PCa
patients urine samples from could be linked to the consumption of this metabolite during the PCa
tumorigenesis process.

However, this would need to be validated experimentally. Moreover,

ethyl α –hydroxymyristate, contains the moiety of 2-hydroxymyristic acid which was reported to
inhibit the myristoylation and alters the stability of p56lckin T cells. p56lck is a protein-tyrosine
kinase that is found predominantly in lymphoid cells

148

, and was reported to be positively

expressed in PCa cell lines and tissues 149, and in metastatic cancer 150.
We also found 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone to
be elevated in the PCa. This compound is the tautomer of 3,5-di-t-butyl-4-hydroxybenzaldehyde
(Figure 4c), a component

of the qHTS assay used to identify small molecule agonists of the RXR

(retinoid X nuclear receptor alpha) signaling pathway: Summary (AID 1159531) 151. The nuclear
expression of RXR alpha receptor subtype was reported to be generally downregulated in human
PCa cell lines and specimens, and the loss or reduction of RXR alpha function is a critical
determinant in prostate tumorigenesis

152

. The high level of 2,6-di-t-butyl-4-hydroxymethylene-

2,3,5,6-detetra-hydrocyclohexanone in PCa positive urine samples may reveal the low utilization
of all those types of agonist of RXR signaling pathway due to the loss of RXR alpha function.
Finally, the low level of estradiol in PCa positive urine samples is consistent with previous studies
identifying low circulation levels of estradiol as a PCa risk factor

153

.

There are several limitations associated with this study. Due to the random nature of
prostate biopsies, it is plausible that PCa negative patients could be misclassified if they harbored
disease missed on prostate biopsy. Secondly, the heterogeneous nature of PCa suggests that the
urinary VOC PCa diagnostic model identified in this study will likely improve as sample size is
increased and more patients from diverse backgrounds and environmental exposures are further
assessed.

While this study focused on urinary VOCs, the role of non-VOC products of

metabolism may also represent important biomarkers that should be accounted for as the final
comprehensive PCa diagnostic model is developed.
44

Finally, the impact of time of urine

collection, diet, disease risk, personal genetic profile and environmental exposures on VOC
concentration measured is unknown but will be addressed in future studies.

2.5

Summary
In summary, the urinary VOCs based model shows promise as a non-invasive and reliable

method for PCa diagnosis. The evaluation in an external cohort of patients, demonstrated the high
discriminating power of this strategy in PCa diagnosis. The urinary VOC based metabolites
approach could likely be adapted into a clinically viable, highly sensitive, cost-effective portable
diagnostic assay for PCa. The validity and effectiveness of those selected VOCs in PCa diagnosis
need to be further confirmed in a larger cohort study. Though the investigation of the originating
pathways of the VOCs selected in the model is beyond the scope of this study, some VOCs linked
to AR modulated pathways were identified in our studies, suggesting a molecular rationale for the
production of these VOCs related to PCa. The biological and chemical significance of these VOCs
could be further studied to provide supporting information for the upstream proteomic pathways.
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Chapter 3: Application of Volatile Organic Compounds (VOCs) in Prostate Cancer Risk
Assessment



Prostate cancer is a heterogeneous disease, ranging from indolent to life threatening stages.



The study was to evaluate the performance of VOCs based model in risk assessment of
prostate cancer. A PCa risk stratification model was developed and validated using
innovative statistical machine-learning techniques.



A VOCs profile screening showed the potential of VOCs for PCa risk stratification.
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Abstract:
Background: Prostate cancer (PCa) is a heterogeneous disease ranging from indolent to life
threatening stages. The choice of watchful waiting or therapies is always depending on the risk
level of PCa. The performance of VOCs has been proved in our previous study to be able to
strongly discriminate PCa patients from controls. We hypothesized that urinary volatile organic
compounds (VOCs) could be used to develop urinary VOC PCa prognostic models for cancer risk
stratification.
Methods: Urine samples from 89 men who presented for transrectal ultrasound guided prostate
biopsy for an elevated PSA or abnormal digital rectal exam were collected. Based on the D’Amico
risk scores system, these PCa patients were divided into two groups: low-risk group (indolent PCa,
GS = 6, PSA< 10, n=55), and high/intermediate-risk group (clinically significant PCa, GS = 6 and
PSA ≥ 10, or GS > 6 with any PSA values, n=34). Urinary metabolites were analyzed by Gas
Chromatography-Mass Spectrometry. Urinary VOCs were screened for significance. A PCa risk
stratification model was developed and validated using innovative statistical machine-learning
techniques.
Results: Using the Wilcoxon rank sum test, 23 VOCs were found to be positively related to
high/intermediate−risk PCa and 44 VOCs negatively associated (p<0.05). Regularized logistic
regression analysis and the Firth method were then applied to predict PCa risk level, resulting in a
final model that contains 11 VOCs. Under cross-validation, the area under the receiver operating
characteristic curve (AUC) for the final model was 0.86 (sensitivity: 0.85; specificity: 0.80), which
indicates a highly promising discrimination power of urinary VOCs in PCa high/intermediate risk
assessment.
Conclusion: The study describes the development of a urinary VOC-based model for PCa risk
stratification and the model shows the potential of VOCs for PCa prognosis.
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Clinical Practice Points
•

Due to the low specificity of current prostate cancer screening with serum Prostate-Specific

Antigen (PSA), up to 80% of men who are found to have elevated PSA value and subsequently
undergo prostate biopsies will either not be diagnosed with prostate cancer (PCa) or be diagnosed
with an indolent form of PCa, which is unlikely to cause significant morbidity or mortality. It is
urgent to address the problem of over-diagnosis and overtreatment in prostate cancer care.
•

We developed urinary metabolites (i.e. VOCs) based model to assess the risk level for PCa

with AUC 0.86, which indicated the great discrimination power of VOCs base model for PCa risk
stratification.

3.1

Introduction
In United States, prostate cancer (PCa) is the most common non-cutaneous cancer and the

second leading cause of cancer death in men.59 In most cases, men, who are diagnosed with PCa,
will ultimately die of other causes. And even with eventually lethal cases, the natural history of
the disease is relatively protracted.154 PCa is a heterogeneous disease ranging from indolent to life
threatening stages. The diagnosis and treatment of PCa is based on a series of clinical states (Figure
3. 1), which begin with localized tumors, followed by the non-castrate state (including rising PSA
state and metastatic state), and finally move to the castration-resistant states.155,156 According to a
decision analysis of alternative treatment strategies for clinically localized PCa carried out by
Fleming et al.157, the choice of watchful waiting is a reasonable alternative to the invasive treatment
for men with localized PCa tumors. However, men with high-risk PCa, who account for 15% of
all PCa diagnosis158, are definitely in need of therapies.
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Figure 3. 1 Clinical states of prostate cancer progression.

The clinicians and researchers have increasingly recognize the importance of risk
stratification of PCa in terms of indolent prostate carcinoma behavior and potential risks of
available treatment159, and the risk-adapted treatment strategies could then be implemented
accordingly. Different risk factors associated with PCa have been integrated into individualized
risk prediction, including PSA, Gleason score, T stage, and other risk factors160. In 1998, D’Amico
et al. developed a combined modality staging system, which stratified PCa patients into groups
with a low, intermediate, or high-risk of biochemical recurrence after radical prostatectomy or
radiotherapy, according to the clinical stage, biopsy Gleason score, and preoperative prostate
specific antigen level. However, the aforementioned risk-assessment factors require invasive
procedure and the accuracy of PSA is questionable. Therefore, there is a significant interest in
finding more sensitive, reliable and cost effective PCa screening and prognosis biomarkers.
VOCs are generated from the human body and thought to reflect the physiological and
metabolic status of the individual

5,135

. Thus, VOCs in individuals with cancer could represent

tumor biology and response to therapy 5. In a recent study with trained dogs, the animals could
smell the urine of men, and discriminate between men with and without PCa with 91% sensitivity
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and specificity 8. The odor is represented by a group of volatile components, i.e. VOCs, and
VOCs profiles can be easily detected using gas chromatography-mass spectrometry (GC-MS), or
gas sensors. 21,44 In our previous study, the performance of VOCs was proven to be able to strongly
discriminate PCa patients from controls.38 It raised the next question whether VOCs can be used
in risk levels differentiation. Herein, we present the first study of the performance of VOCs in
PCa risk stratification.

3.2 Experimental section
3.2.1 Chemicals and Materials
All chemicals, including internal standard (mirex), HCl, methanol, deionized water, were
of analytical grade.38

3.2.2 Patient recruitment and sample collection
In this study, a total of 89 men who presented for transrectal ultrasound guided prostate
biopsy for an elevated PSA above 2.5 ng/ml or abnormal digital rectal exam were included. Based
on the Gleason score (GS) and PSA, these PCa patients were divided into two groups: low-risk
group (GS = 6, PSA< 10) and high/intermediate-risk group (GS = 6 and PSA ≥ 10, or GS > 6 with
any PSA values) as shown in Table 3. 1. The high/intermediate-risk group was considered to be
clinically significant and low risk group as indolent PCa. Urine samples were collected at the
medical facilities and stored at -80 oC until chemical analysis.
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Table 3. 1 Demographic information of prostate cancer patients in the VOC PCa risk assessment
model study. Data are presented as median (interquartile range) for continuous variables and n
(%) for categorical variables.
Prostate cancer patients

N

Low risk

High and intermediate risk

34

55
5.29 (0.08-1987)

PSA (ng/mL)
3.95 (0.10–9.33)

6.21 (0.08-1987)

0.22

6-9

Gleason score
6

p valuea

34 (100)

7

38 (69)

8

11 (20)

6 (11)
9
a. The p value from the t-test of the PSA numbers between low grade and high risk group.

3.2.3 Extraction of VOCs from urine samples
Urine samples were processed through centrifuging and stir bar sorptive extraction.38

3.2.4 Gas Chromatography-Mass Spectrometry analysis
Briefly VOCs from urine samples were analyzed in a thermal desorption unit, TDU
(Gerstel), coupled with a Gas Chromatography-Mass Spectrometry (GC/MS) system. The
National Institute of Standards and Technology (NIST) Library was used for the identification of
VOCs profile in urine sample.38

3.2.5 Data processing and statistical analysis
We have implemented internal standard method in the analysis. Mirex was used as the
internal standard for its non-existence in urine. The relative intensity of each VOC peak could then
be normalized against that of Mirex to enable semi-quantitative analysis of VOCs in the statistical
analysis. The statistical significance of each VOC was tested by Wilcoxon test. Heat maps were
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generated to visualize significant VOCs (p<0.05) among the high/intermediate risk group and low
risk group. Applying a liberal cutoff at p=0.2, a larger size of VOCs were included to develop a
logistic regression model for PCa risk assessment. The VOC based model was then evaluated by
cross-validation.
Briefly, the VOC-based diagnostic tool was developed via logistic regression. The final
logistic model was evaluated via the Receiver Operating Characteristic (ROC) curve and its
associated performance was measured on the basis of its jackknife prediction. All the analyses are
performed using the open-source statistical computing package R.38

3.3 Results
A total of 89 PCa patients (55 High/intermediate risk PCa patients and 34 low risk PCa
patients) were recruited for the study. There were 8,194 VOCs found in urine from the subjects.
Using the Wilcoxon rank sum test, 23 VOCs were found to be positively related to high−risk PCa
and 44 VOCs negatively associated at p<0.05, as shown in Figure 3. 2. After variable screening,
289 potential VOCs (p < 0.2) were selected for model development. The 𝑙1 –regularized logistic
regression resulted in a final model that included 11 VOCs as listed in the Table 3. 2. On the basis
of predicted probabilities computed via Jackknife, the area under the receiver operating
characteristic (ROC) curve is 0.86 as shown Figure 3. 3, and the sensitivity and specificity were
85% and 80% respectively, which indicates a highly promising discrimination power of urinary
VOCs in PCa high risk assessment.
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Figure 3. 2 The heat map of significant VOCs by Wilcoxon test (p <0.05) in high/intermediate
risk vs low risk prostate cancer groups. The correlation between VOCs and patients ranges from
low (red) to high (blue).
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Table 3. 2 VOCs from logistic regression models for prostate cancer risk assessment

CAS
Number

Dominating
Group

Formula

031061-61-7

C13H20O2

018127-01-0

C13H18O

Tricyclo[4.3.1.1(3,8)]undecane-3carboxylic acid, methyl ester
4-(1,1-dimethylethyl)-benzenepropanal

007206-21-5

C18H36

020607-72-1

Chemical Name

Occurrence
High/intermediate
Low risk
risk

Low Risk

2

5

Low Risk

1

5

5-Octadecene, (E)-

High Risk

14

15

C6H14N2

Acetaldehyde, butylhydrazone

Low Risk

19

3

046498-17-3

C13H13N3

3,6-Diamino-9-methylcarbazole

High Risk

0

5

000111-06-8

C20H40O2

Hexadecanoic acid, butyl ester

Low Risk

3

8

131316-14-8

C17H16OS

Low Risk

1

9

092617-73-7

C13H18O

Low Risk

16

3

054340-85-1

C12H16

trans-3'-Methyl-4-(methylthio)chalcone
2-(1,1-dimethyl-2-propenyl)-3,6-dimethylphenol
1-(2-butenyl)-2,3-dimethyl-benzene

Low Risk

2

6

001153-51-1

C19H30O

(3alpha,5alpha)-androst-16-en-3-ol

Low Risk

2

6

000621-42-1

C8H9NO2

Metacetamol

Low Risk

1

5
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Figure 3. 3 The ROC curve for PCa risk assessment logistic model verified in 89 patients.

3.4 Discussion
In this study, the VOCs based PCa risk assessment model has exhibited the potential to
discriminate PCa high/intermediate risk group patients from low risk PCa patients. Additional to
the well-known risk factors, age, PSA, family history, DRE findings, and outcomes of prior biopsy,
VOCs would be considered as another risk factor in PCa risk stratification.
The study of VOCs in PCa risk assessment has identified 11 VOCs in the final model with
AUC 0.86, which has suggested a promising role of VOCs in PCa risk stratification. There are also
other risk prediction tools being developed to implement the PCa diagnose and risk evaluation.
Tomlins et al.161 reported urine TMPRSS2:ERG fusion transcript, in combination with urine
PCA3, could be used in PCa risk stratification of men with elevated serum PSA, with AUC ranging
from 0.71 to 0.79. In the study Rastinehad et al.162, using multi-parametric magnetic resonance
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prostate imaging (MRI) may assess the degree of risk associated with magnetic resonance visible
lesion in the prostate based on the D’Amico risk scores.
Among 11 VOCs selected by the regression mode of PCa high risk vs PCa low risk, 9
VOCs were negatively associated with escalating PCa risk and the remaining 2 were positively
associated as listed in Table 3. 2. Androstenol, dominating in PCa low risk group, has a structure
similar to that of androgens. Androstenol could be efficiently transformed from the precursor
5,16-androstadien-3β–ol (a sex steroid) through enzymatic activities including 3β-hydroxysteroid
de-hydrogenase, 5α-reductase and 3α-hydroxysteroid dehydrogenase 163. Of those three enzymes,
3β-hydroxysteroid de-hydrogenase and 5α-reductase were reported to be involved in PCa
development and progression 164,165. And studies also showed that androstenol could modulate the
activity of CAR (constitutive androstane receptor) and PXR (pregnane X receptor, also known as
steroid and xenobiotic receptor SXR) and the expression of some cytochrome P450 drugmetabolizing enzymes 166,167. A combined analysis with CYP3A4 expression revealed that the low
expression of the SXR and CYP3A4 was a significantly unfavorable prognostic factor for PCa in
a multivariate analysis. It was suggested that the downregulation of the SXR, and consequently,
its target CYP3A4 gene might play a significant role in PCa progression. Androstenol might exert
tumor-inhibitory effects on PCa by increasing SXR expression and enhancing androgen clearance
168

. Therefore, the lower level of androstenol in the high risk group was consistent with the reported

biological effect, i.e. relating the down regulation of SXR activities with the progression of PCa.

Figure 3. 4 The chemical structure of Androstenol.
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3.5 Summary
Using VOCs in urine is a non-invasive and promising method for PCa risk assessment. The
biological and chemical significance of some selected VOCs in this study could link to specific
metabolic pathways in PCa progression and could be further studied to provide supporting
evidence for the upstream proteomic pathways. Even with a considerably small sample size, the
VOC models showed very promising discriminating power between high risk and low risk PCa.
Our results showed that urinary VOCs could likely be translated into a clinically viable, highly
sensitive, cost-effective portable diagnostic assay for PCa and may help identify patients with
clinically significant PCa. For future study, the validity and effectiveness of those selected VOCs
in PCa risk assessment may be further confirmed in a larger cohort.
Risk assessment is a critical aspect of PCa treatment decision-making. Hernandez et al. did
a contemporary evaluation of the D’Amico risk classification of PCa.169 They concluded from their
study that the clinical relevance of this classification scheme may be limited and diminishing in
the contemporary era. Besides the D’Amico classification, there are some other approaches to risk
assessment of PCa, including a variety of nomograms170 and UCSF-CAPRA Score171. The
different risk classification methods would be applied in the further development and evaluation
of VOCs based PCa model.
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Chapter 4: Application of Urinary Volatile Organic Compounds (VOCs) for the diagnosis
of Renal Cancer



This chapter described the development of a diagnostic tool for clear cell renal cell
carcinoma.



Urine samples were collected from 108 patients who were imaging and/or surgery proven
of clear cell renal cell carcinoma positive or negative.



Urinary metabolites were analyzed to develop a metabolomics based model to detect clear
cell renal cell carcinoma.



The model was validated in a second cohort of patients and showed high discriminating
power in clear cell renal cell carcinoma detection.
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Abstract:
Background:

Kidney cancer (renal cancer) accounts for more than 2% of cancer incidence and

mortality in the United States The outcome of renal cell carcinoma (RCC) is usually unpredictable
even after a long period of asymptomatically development and progression., its diagnosis is often
incidental through the use of medical imagology and it is frequently at an advanced stage and
metastatic when detected. Therefore, a fast and reliable early screen of renal cell carcinoma (RCC)
enables better treatment outcome and care in patients. Clear cell RCC accounts for 70–80% of all
kidney cancers. However, there is no recommended screening tests for RCC available clinically.
This study developed a non-invasive and fast urine based diagnostic tool and evaluated its clinical
utility, sensitivity and specificity to screen clear cell RCC (ccRCC, the main type of RCC) in
populations.
Methods: Two cohorts were recruited for the study – a training cohort for model development and
a testing cohort for model validation. For the training cohort, a total of 108 urine samples were
obtained from 71 patients who were undergoing partial or radical nephrectomy and 37 patients
ccRCC negative based the imaged renal mass.

Specific volatile organic compounds (VOCs) in

urine were analyzed by Stir Bar Sorptive Extraction coupled with Thermal Desorption-Gas
Chromatography/Mass Spectrometry. All VOCs were analyzed based on their occurrence and
relative quantity in the urine. The significant VOCs were screened by Wilcoxon Rank Sum Test.
A VOCs based ccRCC diagnostic model was developed through the logistic regression in training
group (57 ccRCC vs 31 controls) and validated in the testing group (14 ccRCC vs 6 controls).
Results: A total of 8,266 VOCs were found in the urine samples of training set.

Using Wilcoxon

Rank Sum Test in screeing their bivariate association with ccRCC, 79 VOCs were found to be
related to urine samples of ccRCC positive patients while 91 VOCs corresponding to RCC
negative controls (p<0.05). After further selection with 𝑙1

regularization, 15 VOCs were

included in the RCC diagnostic logistic model. On the basis of predicted probabilities from the
model via cross-validation, the area under the receiver operating characteristic curve (AUC) was
found to be 0.87 and the sensitivity and specificity were 93% and 77% respectively. The VOCs
59

based RCC diagnostic model were then validated in the testing group. The results showed a
promising diagnostic power of this VOCs model in ccRCC screening with 0.81 AUC, 86%
sensitivity and 83% specificity respectively.
Conclusion: This is the first systematic study to demonstrate and validate the clinical utility of a
non-invasive urinary VOCs based diagnostic model in ccRCC screening. The VOCs based
diagnostic model has the substantial potency and clinical value in RCC screening, and the
analytical method was fast and highly translatable.
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Clinical Practice Points
•

No early screening method is recommended to screen for kidney cancer in people at

average risk or increasing risk.
•

We developed urinary metabolites (i.e. VOCs) based model to detect ccRCC with a high

accuracy (87.5%) in ccRCC screening, thus potentially providing a new tool to accurately and
reliably diagnose clear cell renal carcinoma.
•

As a non-invasive and sensitive tool, the VOC model is ideally suited for early diagnosis

of ccRCC. Future validation of our model will enable clinically relevant and cost-effective, pointof-care ccRCC screening and prognosis with the potential to save health care costs.

4.1

Introduction
Kidney cancer accounts for more than 2% of cancer incidence and mortality in the United

States, which would include nearly 65,340 new cases (3.8%) and 14,970 deaths estimated for
2018.59 The most common type of kidney cancer is renal cell carcinoma (RCC), about 9 RCC out
of 10 kidney cancers. RCC is a heterogeneous malignancy, both morphologically and genetically,
which is classified into different histologic subtypes, including clear cell RCC (ccRCC), papillary
RCC, chromophobe RCC and other less common subtypes.74-76 The most common subtype is
ccRCC, accounting for 70–80% of all kidney cancers, which is so named because the high lipid
content in the cytoplasm is dissolved during histological preparation methods leaving a clear
cytoplasm.172
The outcome of RCC is usually unpredictable even after a long period of asymptomatically
development and progression.77 Therefore, its diagnosis is often incidental through the use of
medical imagology and it is frequently at an advanced stage and metastatic when detected
clinically.78 However, no early screening method is recommended to screen for kidney cancer in
people at average risk or increasing risk.
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With the recognition of reprogramming metabolism as a central hallmark of cancer,
metabolomic approaches have shown promise in oncology diagnosis and treatment.129 Therefore,
the applications of metabolomics are increasingly in the discovery and validation of biomarkers
for cancers, which might not only improve early detection but also enable the outcome and
recurrence prediction of disease. In a recent studies, trained dogs could differentiate men with and
without cancers, like bladder cancer, prostate cancer and lung cancer, by sniffing their urine with
high sensitivity and specificity.8-10 The odor of urine is from so-called volatile organic compounds
(VOCs) which can be generated from the human body and released through breath, blood, skin,
urine and feces.135 These VOCs are thought to reflect the physiological and metabolic status of the
individual.

5

Thus in individuals with cancer, the VOCs could represent tumor biology and

response to therapy.5 In general, RCCs are epithelial tumors in contact with the urinary space173,
making this cancer well suited for a metabolomic approach through the VOCs analysis of urine.
VOCs can be easily detected using gas chromatography-mass spectrometry (GC-MS), or
gas sensors.21,44 We had demonstrated a successful application of VOCs in prostate cancer
screening and prognosis.38 The purpose of this study was to test the hypothesis that urinary VOCs
based diagnostic model could be used in ccRCC early screening.

4.2 Experimental section
4.2.1 Study Design
Approval was obtained from the Internal Review Board (UTEP and Geisinger), and written
informed consent was obtained from all patients. For ccRCC diagnostic model development, 108
urine samples in total were obtained from a) 71 patients preoperatively on the day of surgery who
were undergoing partial or radical nephrectomy with a presumptive diagnosis of ccRCC based on
a CT imaged renal mass (and whose postoperative pathology diagnosis established clear cell renal
carcinoma cancer); and b) 37 patients RCC negative based the imaged renal mass.
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Patients were divided into two groups: training group (for model development) and testing
group (for model evaluation). The training set contained urine samples from 57 pathologically
diagnosed ccRCC patients and 31 RCC negative control patients. For the testing group which was
to evaluate the final performance of the ccRCC diagnostic model, 14 ccRCC patients and 6 RCC
negative controls were involved. The demographic data are shown in Table 4. 1. Urine samples
of the subjects were collected at the medical facilities and stored at -80 oC until chemical analysis.
Table 4. 1. Demographic information of clear cell renal cell carcinoma and renal cancer-negative
patients in the VOC ccRCC diagnosis model development. Data are presented as median
(interquartile range) for continuous variables and n (%) for categorical variables.
Training Cohort (Model
Development)

No.
Age
Gender
M
F
Tumor
grade*
1
2
3
4

Cancer Group

Control Group

57
64 (40-90)

31
64 (40-90)

36
21

23
8

Testing Cohort (Model
Evaluation)
Cancer
Control
Group
Group
14
6
63.5 (52-82)
53 (38-65)
10
4

N/A
3 (5%)
24 (42%)
18 (32%)
12 (21%)

6
0
N/A

0 (0%)
8 (57%)
4 (29%)
2 (14%)

* Pathology/Biopsy Confirmed Dx (Tumor grade)

4.2.2 Chemicals and Materials
Briefly, all chemicals, including mirex, HCl, methanol, deionized water, used were of
analytical grade.38

4.2.3 Extraction and Chemical analysis of VOCs from urine samples
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Urine samples were processed through centrifuging and stir bar sorptive extraction.38
Briefly, VOCs from urine samples were analyzed in a thermal desorption unit, TDU (Gerstel),
coupled with a GC/MS system. The National Institute of Standards and Technology (NIST)
Library was used for the identification of VOCs profile in urine sample. All samples were analyzed
in a blinded and coded fashion in instrument analysis.38

4.2.4 Data processing and statistical analysis
The detailed analysis was previously published.38 Mirex was used as the internal standard.
The relative intensity of each VOC peak could then be normalized against that of Mirex to enable
semi-quantitative analysis of VOCs in the statistical analysis. The statistical significance of each
VOC was tested by Wilcoxon test. Heat maps were generated to visualize significant VOCs
(p<0.05) among the ccRCC positive and control groups. Applying a liberal cutoff at p=0.2, a larger
size of VOCs was applied to develop a logistic regression model was applied for further selection
of noteworthy VOCs.
The VOC-based diagnostic tool was developed via logistic regression 136. The final logistic
model was evaluated via the Receiver Operating Characteristic (ROC) curve and its associated
performance was measured on the basis of its jackknife prediction (Kleinbaum and Klein, 2010
138

). All the analyses are performed using the open-source statistical computing package R.141

4.3

Results
All VOCs were identified based on their occurrence and relative quantity in the urine. The

relative quantity of each VOC was determined through being normalized by the spiked Mirex (the
internal standard, IS, for it has no inference with the VOCs in vivo.)
A total of 8,266 potential VOCs were detected in urine collected from the training cohort
which consisted of 57 ccRCC patients and 31 age matched negative controls. Using the Wilcoxon
rank sum test at statistical significance p=0.05, 79 VOCs were found to be related to cancer group
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urine samples and 91 VOCs corresponding to controls. The distribution of those selected VOCs in
patients was shown in Figure 4. 1a).
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Figure 4. 1. a) The quantity heat map of significant VOCs in clear cell renal cell carcinoma
(ccRCC) vs controls samples by Wilcoxon test (p <0.05).; b) the quantity heat map of 15 selected
VOC metabolites selected by ccRCC diagnostic model in the urines of the training cohort
patients . The Chemical Abstracts Service (CAS) numbers were used to indicate each metabolite.
The correlation between VOCs and patients ranges from low (red) to high (blue).
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To develop the regression diagnostic model, a broader range of VOCs were selected using
p=0.20.

As a result, 442 potential VOCs were identified. After further selection with 𝑙1

regularization, the final logistic model selected 15 VOCs (listed in the Table 4. 2) Among the 15
VOCs, 13 were dominated in control group and 2 dominated in cancer group as shown in Figure
4. 1b).
The performance of this ccRCC diagnostic model was validated in those 88 patients. On
the basis of predicted probabilities from the final model via jackknife cross-validation, the area
under the receiver operating characteristic (ROC) curve (AUC) was 0.87 with confidence interval
0.77 to 0.97 as shown in Figure 4. 2), which indicated a highly promising discrimination power
between VOCs in urine of ccRCC patients and controls. The sensitivity and specificity of this
ccRCC diagnostic model (normalized to Mirex) to identify patients with ccRCC was determined
using ROC analysis. Compared to controls, this diagnostic model had 93% sensitivity and 77%
specificity, with a cut-off point set at 0.68.
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Table 4. 2. The VOCs selected by logistic regression models for clear cell renal cell carcinoma diagnosis prediction.
CAS
Number1
000123-95-5
000613-13-8
000292-64-8
002136-72-3
1000272-007
013450-73-2
013019-20-0
007726-08-1
002216-32-2
1000122-559
007496-81-3
031083-60-0
056114-69-3
000275-51-4
002919-23-5

Formula

Dominating

Chemical Name

Group

C22H44O2
C14H11N
C8H16
C20H42O2

Octadecanoic acid, butyl ester
2-Anthracenamine
Cyclooctane
Ethanol, 2-(octadecyloxy)1,2,4-Oxadiazole, 5-methyl-3-(1C9H15N3O
piperidylmethyl)11H-Dibenzo[b,e][1,4]diazepin-11-one,
C16H17N3O
5-(3-aminopropyl)-5,10-dihydroC8H16O
3-Heptanone, 2-methylC12H25NO2
Decanamide, N-(2-hydroxyethyl)C9H20
Heptane, 4-ethyl1,3-Bis-(p-carbamoylmethylphenoxy)C19H22N2O5 2-propanol
C15H13N
Indolizine, 2-(4-methylphenyl)Tricyclo[4.3.1.1(3,8)]undecane-1C13H20O2
carboxylic acid, methyl ester
Benzaldehyde, 2,5C13H22O3Si2 bis[(trimethylsilyl)oxy]C10H8
Azulene
C4H8O
Cyclobutanol

1 Chemical Abstracts Service number
2 p value: the p value of selected compounds from Wilcoxon rank-sum Test
3 Cancer (+): clear cell renal cell carcinoma positive patient
4 Control (-): renal cancer negative patent
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Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Cancer
Cancer

p value2
1.28E-05
4.54E-04
1.49E-03
1.61E-03
1.99E-03
1.99E-03
1.99E-03
1.99E-03
1.14E-02
3.08E-02
4.81E-02
8.74E-02
1.01E-01
2.83E-03
2.11E-02

Occurrence
Cancer(+)3 Control(-)4
1
4
4
6

11
11
10
12

0

5

0

5

0
0
2

5
5
6

3

6

5

7

2

4

40

26

18
48

1
23

To evaluate the performance of the above ccRCC diagnostic model, a second cohort of
patients as the testing group were recruited, and the VOCs in their urine were analyzed. Via
Jackknife cross-validation, the area under the ROC curve was 0.81 with confidence interval 0.52
to 1 as shown Figure 4. 3), and had 86% sensitivity and 83% specificity (with cutoff point at 0.68).
The results revealed the promising discrimination power of urinary VOCs in ccRCC diagnosis.

Figure 4. 2. The ROC curve for VOC ccRCC diagnosis logistic model verified in the training
group with 88 patients.
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Figure 4. 3. The ROC curve for VOC ccRCC diagnosis logistic model tested in the testing group
with 20 patients.

4.4

Discussion
This investigation was designed to evaluate the clinical utility of the urinary VOCs statistic

model for the diagnose ccRCC. Screening through over eight thousands VOCs in urine using
logistic regression, the diagnostic model including 15 VOCs was developed. The major findings
in this study indicate that the VOCs based ccRCC diagnostic model had favorable sensitivity and
specificity. With the area under ROC was 0.87 and 0.81, and the high sensitivity (93% and 86%)
and the specificity (86% and 83%) for training data set and testing data set, respectively, the model
demonstrated the clinical validity of this VOCs based ccRCC diagnostic model.
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To our

knowledge, it is the first model of its kind for ccRCC detection.

The model offers a great

potential for develop the first cost effective and non-invasive screening tool for ccRCC.
The analytical method developed in this study allowed an easy, fast and efficient analysis
of VOCs without tedious sample preparation. The solventless sample preparation technique, Stir
Bar Sorptive Extraction, can preserve the sample integrity and permit effective analyses for
processing large sample sizes which will be an important factor for clinical translatability. Unlike
gas-sensor (such as E-nose)44, the GC/MS can provide much detailed information on the
compound identity for future metabolomics and physiological studies. In this study, the VOCs
detected in each sample were confirmed through the NIST library report. All samples were
analyzed in a blinded and coded fashion in instrument analysis.
We also introduced an internal standard so that we were able to perform semi-quantitative
analysis (i.e. relative peak area ratio to internal standard) for each VOC in the statistical
examination. Mirex was selected as the internal standard because of its non-existence in human
and a relative longer retention time in GC so it will not interfere with the urinary VOCs in the
analysis. All the VOCs signal intensities were then normalized to that of mirex.
Unlike the determination protein biomarkers, urine aquaporin-1 (AQP1) and perilipin2(PLIN2), of RCC reported by Jeremiah J. Morrissey et al82, the concentration of VOCs in this
study was not normalized to the concentration of urine creatinine, which is suggested to be used
to minimize the impact of hydration status from patient to patient or in the same patient over
time174, because 1) there is a significant lag between the time of injury in kidney and the time that
the concentration of creatinine achieve the threshold required to diagnosis kidney disease, which
reveal the possible inconsistent concentration of creatinine; 2) there is no significant differences
observed between creatinine normalized and non-normalized results in this protein biomarkers
paper; and 3) this investigation is designed to test the performance of novel VOCs based model in
ccRCC diagnosis without normalizing to any biomarker of renal disease.
Five phases of screening biomarker development were proposed Margaret Sullivan Pepe
et al 2001.174 However, our study didn’t progress consecutively through those five phase. In this
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investigation, the training and testing set design began with phase 2, clinical assay and validation,
and phase 3, retrospective longitudinal. The phase 1, preclinical exploratory, are being investigated
along with the phase 2 and phase 3 in this study.

Furthermore, even though the two urinary

exosomal proteins, AQP-1 and PLIN2, have shown promise as the biomarkers in RCC diagnosis,
they can be found in clear cell and papillary RCC but not in the chromophobe subtype of RCC. 82
Our VOCs based screening model, however, has great potential to be developed as a more
universal screening tool of almost all types of RCC because of the metabolic distinction shown
between cancer patients and controls. Unlike the ELISA detection methods of AQP-1 and PLIN2,
the VOCs based diagnostic model is a high throughput and fast screening method in clinical
applications enabled by high performance SBSE, GC/MS and statistical analysis.
The potential of urinary VOCs used in RCC diagnose has been highlighted in previous
studies.22,80,81 Most of the studies focused on the search of specific VOCs in RCC patients without
further validation.22,80 In the study reported by Marica Monteiro in 201781, the selected VOCs was
validated in different patients group for the existence, but the performance (discrimination power)
of VOCs in differentiating RCC patients and controls was not determined. Our study, however,
have shown the prediction power of the VOCs based diagnostic model which was determined
through the statistical analysis with AUC, sensitivity, specificity, and accuracy calculation.
Another major difference is the introduction of internal standard, Mirex, which enables the relative
more accurate quantity determination of VOCs in urine.
We further studied the VOCs selected for the ccRCC screening model. When examining
their chemical structures, Octadecanoic acid-butyl ester, cyclooctane, 2-(octadecyloxy)-ethanol,
2-methyl-3-heptanone, cyclobutanol, 4-ethyl-heptane, and N-(2-hydroxyethyl)-decanamide may
be involved in peroxidation of fatty acids because of the long carbon chain and/or carbanyl group.
Octadecanoic acid-butyl ester and 2-(octadecyloxy)-ethanol could be the peroxidation products of
oleic acid (C18H34O2), which is one of the main (poly) unsaturated fatty acids (P)UFA in vivo and
has potent anti-inflammatory properties.175,176 In the structure of N-(2-hydroxyethyl)-decanamide,
a compound in control group, the moiety of ethanolamine can be formed through the
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decarboxylation of serine or the reduction of glycine.177 Ethanolamine, serine, glycine and
sarcosine are closely interrelated in several one-carbon metabolic cycles. One-carbon metabolism
integrates cellular nutrient status by cycling carbon units from amino acid inputs to generate
diverse outputs, including redox maintenance and cellular biosynthesis 99. Genetic and functional
evidence suggests that hyper activation of those pathways is a driver of oncogenesis and
establishes a link to cellular epigenetic status

99

. Additionally, the plasma membrane of normal

cells is characterized by an asymmetric distribution of various phospholipids over two membrane
leaflet. Phosphatidylethanolamine (PE) resides in the inner leaflet facing the cytosol. The disrupted
membrane asymmetry of cancer cell exposes PE to extracellular space 124, and the increasing need
of PE in cancer cell may correlate the excessive consumption of ethanolamine (which was found
to be mostly appear in control group in our study) and enhanced lipogenesis.
This study had cover three of the five phases of screening biomarker development proposed
by Margaret Sullivan Pepe et al 2001.174 In this study, the training and testing set design began
with phase 2, clinical assay and validation, and phase 3, retrospective longitudinal. The phase 1,
preclinical exploratory, are being investigated along with the phase 2 and phase 3 in this study.
One of the aims in this investigation was to test the value of VOCs based ccRCC diagnostic model
to screen and identify ccRCC. Even with a considerably small sample size, the VOCs based model
showed very promising discriminating power between ccRCC and control patients.

A future

study could include larger cohort of patients and expand to other types of RCC.

4.5

Summary
This investigation was designed to evaluate the clinical utility of the urinary VOCs statistic

model for the diagnose ccRCC. The findings indicated that the VOCs based ccRCC diagnostic
model had favorable sensitivity and specificity. With the area under ROC was 0.87 and 0.81, and
the high sensitivity (93% and 86%) and the specificity (86% and 83%) for training data set and
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testing data set, respectively, This investigation supports the ability of urinary VOCs based
diagnostic model to early and non-invasive screening ccRCC patients.
Overall, it validates the clinical utility of urinary VOCs based diagnostic model as the
biomarker for ccRCC. In addition, the validation of those selected VOCs in a larger cohort would
confirm the statistical significance in ccRCC screening and even in ccRCC staging diagnose.
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Chapter 5: Cross Examination of Volatile Organic Compounds (VOCs) based models in
prostate cancer and clear cell renal carcinoma diagnosis



Two urinary VOCs based models were independently developed previously for prostate
cancer (PCa) and clear cell renal cell carcinoma (ccRCC). This chapter was to cross
examine the VOC-PCa model on ccRCC and the ccRCC VOC model on PCa detection, to
study the model cancer specificity for the two promising cancer diagnostic models.



The area under received operation curves from the validations verifies the cancer specific
discrimination power of the VOCs models for PCa and ccRCC screening.
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Abstract:
Background: In our previous studies, the VOCs based diagnosis models were respectively
developed and validated in different cohort of patients to differentiate PCa and ccRCC patients.
To test the performance of the models with increased complexity, we reevaluated the performance
of those two VOCs models.
Methods: Two previously developed urinary VOCs based models were included in this study:
PCa model (11 VOCs included) and ccRCC model (15 VOCs included). Four patient groups
involved in this study were 55 PCa positive patients, 53 PCa negative patients, 55 ccRCC positive
patients and 31 RCC negative patients as a larger cohort. The performance of PCa model to
differentiate PCa positive patients from others and ccRCC model to differentiate ccRCC positive
patients from others were evaluated via the Receiver Operating Characteristic (ROC) curve.
Results: The discrimination power of PCa model resulted in an area under ROC curve (AUC) of
0.834 with confidence interval of 0.779 to 0.889. Then, after testing the ccRCC model, the AUC
was 0.779 with confidence interval 0.707 to 0.851.
Conclusion: The study verified the discrimination power of the PCa model and ccRCC model
with increased population complexity.
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Clinical Practice Points
•

The internal validation results of two urinary VOCs based models, PCa model and ccRCC

model, were cross examined on patients who have different types of cancer.

The patient

complexities in clinical practice and the specificity of those cancer diagnostic models should be
taken into consideration.
•

We cross examined the PCa model and ccRCC in a larger sample pool with increased

patient complexity. The results from the logistic regression showed good outcomes (i.e. high
AUC), which verified the reliability of VOCs based cancer diagnostic models for prostate cancer
and clear cell renal carcinoma diagnosis.
•

As a non-invasive and sensitive tool, the VOC model is ideally suited for early diagnosis

of PCa and ccRCC. Future validation of our models will enable clinically relevant and costeffective, point-of-care PCa, ccRCC and even other urinary tract cancers screening and prognosis
with the potential to save health care costs.

5.1

Introduction
In our previous studies, the VOCs based diagnostic models were developed and validated

in different cohorts of patients to differentiate prostate cancer (PCa), and clear cell renal cell
carcinoma (ccRCC) patients from controls patients. The increasing availability and use of
predictive models highlights the need for careful assessment of the validity of these models. 178
Meanwhile, the challenges of validating a biomarker-based predictive model are considerable, and
the validation process should be planned as early as possible in the design phase of risk prediction
model development.
Validation requires a comparison of model prediction with a “gold standard”, i.e. the true
outcome.178 The “gold standard” must be ascertainable or observable in the future and might be
able to indicate whether the patient has cancer or will they eventually have a recurred cancer
confirmed by a procedure (such as biopsy) or long term follow-up. For example, the true outcome
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in the Prostate Cancer Prevention Trial (PCPT) is prostate cancer status obtained via biopsy.160
The input data, prediction, and all the other available truth for the patients are all required in the
validation. Furthermore, the larger validation data sets are preferable and crucial in the evaluation
of a risk model. In general, there are two forms of validation, internal validation and external
validation.178 Internal validation involves training-testing splits of the available data and/or cross
validation, as designed in our previous studies (chapter 2 and 4).38 It can provide the valid
assessment of model performance in disease risk prediction. External validation are conducted
through a different data set collected by different investigators from different institutions.
Validation on heterogeneous external data sets allow for the evaluation of predictive model on
populations other than the one on which the model was developed.178 For example, different
geographic locations or different clinical practices would contribute to the difference of the
populations.
The internal validation results from our research have revealed the great potential of those
VOCs based models to facilitate informed decision making in clinical practice. However, the
population complexities in clinical practice and the specificity of those cancer diagnostic models
should be taken into consideration. The VOCs based diagnostic models were developed based on
the patients who were confirmed with particular cancer (either prostate cancer or renal cancer) by
clinical procedures, and those models are expected to be used in early screening and diagnosis of
PCa and ccRCC. The ability of those VOCs based models to differentiate PCa or ccRCC patients
from other urinary tract cancers is unknown. Therefore, the objective of this investigation was to
conduct a “pre-external validation” and cross examine the discrimination performance of the PCa
and ccRCC model among the patient groups who either have different type of cancer or other
medical conditions not related to the disease of the model.

In this study, we hypothesized that

the VOCs found in either PCa or ccRCC are cancer specific. Therefore the cancer specific VOC
models would be able to differentiate PCa or ccRCC cancer patients from those who do not have
these specific cancer regardless of the possible existence of other cancer.

78

5.2 Experimental Section
5.2.1 Study Design
This study was aimed to conduct the “pre-external validation” and reevaluate the
discrimination performance of the above VOCs based PCa model and ccRCC model for the cancer
type specificity and larger sample validation. PCa model was tested between PCa patients and
those who do not have PCa, e.g. ccRCC patients plus all the controls; and the ccRCC model was
tested between ccRCC and those who do not have ccRCC, e.g. PCa patients plus all the controls
(Figure 5.1).
Patient recruitment and approval procedures followed the same procedures as described in
chapter 2 and 4.

Briefly, approval was obtained from the Internal Review Board, and written

informed consent was obtained from all patients. Both PCa Patients presented to Geisinger
Medical Center urologic clinic for evaluation of elevated PSA >2.5 ng/ml or abnormal digital rectal
exam and their cancer status was confirmed by prostate biopsy.
status were confirmed by CT imaging procedure.

As for ccRCC groups, cancer

All patients provided urine specimens for

dipstick urinalysis and the remaining urine samples (50 ml) were collected and stored at -80oC
prior to VOC analysis. In this study, 55 diagnosed with PCa, while 53 were negative for PCa; 57
patients with ccRCC and 31 patients RCC negative based the imaged renal mass. The demographic
information of all those patients are shown in Table 5. 1.
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Table 5. 1 Demographic information of prostate cancer, clear cell renal carcinoma, and control
patients in the reevaluation of VOCs based cancer diagnostic models. Data are presented as
median (interquartile range) for continuous variables and n (%) for categorical variables.
Prostate cancer patients
Cancer patients

Controls

N

55

53

PSA (ng/mL)

5.29 (0.08-1987)

2.6 (0.1-18.2)

a

Gleason score
6
7
8
9

p value b

0.28

N/A
20 (36%)
23 (42%)
6 (11%)
6 (11%)
Renal cancer patients
Cancer patients

Controls

N
57
31
Tumor grade c
N/A
1
3 (5%)
2
24 (42%)
3
18 (32%)
4
12 (21%)
a. PSA: prostate specific antigen
b. The p value from the t-test of the PSA numbers between prostate cancer and control groups
c. Pathology/Biopsy Confirmed Dx (Tumor grade

The validation procedures in this study will be divided into two parts shown in as shown
in Figure 5. 1 1) PCa diagnostic model would be validated in the PCa (+) and all other three groups
(i.e. ccRCC patients, ccRCC (-) and PCa (-); 2) ccRCC diagnostic model was validated in the
ccRCC and all other ccRCC negative group (i.e. ccRCC (-), PCa (+) and PCa (-).
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Figure 5. 1 The study design of reevaluation of 11 VOCs based PCa diagnostic model and 15
VOCs based ccRCC diagnostic model

5.2.2 Data processing and statistical analysis
The cross examination of PCa and ccRCC logistic models were evaluated via the Receiver
Operating Characteristic (ROC) curve and its associated performance was measured on the basis
of its jackknife prediction (Kleinbaum and Klein, 2010 138). All the analyses are performed using
the open-source statistical computing package R141. The details were previously published in by
Gao et al.38

5.3 Results
There were 11 VOCs included in the PCa logistic model while the ccRCC logistic model
selected 15 VOCs. As shown in .
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Table 5. 2 there is no duplicated VOCs between those two groups: these 11 VOCs for PCa
diagnosis and 15 VOCs for ccRCC diagnosis.
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Table 5. 2 11 VOCs selected in prostate cancer diagnostic models and 15 VOCs selected in clear cell renal carcinoma diagnostic
models.
11 VOCs PCa model
CAS
Number
000472-41-3
000050-28-2
129086-73-3
1000215-252
1000126-505

4-(3,4-dihydro-2,2,4-trimethyl-2H-1benzopyran-4-yl)-phenol
Estradiol
Ethyl à-hydroxymyristate trisiloxane
1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl2)propane
2-amino-Imidazole-5-carboxylic acid

020548-62-3
024535-53-3
075132-80-8

1-Propylpentachlorotriphosphazene

101100-38-3

2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6detetrahydrocyclohexanone

003555-47-3

CAS
Number

Chemical name

1,1,3,3,5,5,7,7,9,9-decamethylpentasiloxane
1,1,1,5,5,5-hexamethyl-3,3bis[(trimethylsilyl)oxy]-Trisiloxane
Phthalic acid, bis(7-methyloctyl) ester
4-Nitro-4'-chlorodiphenylsulfoxide

000995-83-5

15 VOCs ccRCC model
Chemical name

000123-95-5

Octadecanoic acid, butyl ester

000613-13-8
000292-64-8

2-Anthracenamine
Cyclooctane

002136-72-3

Ethanol, 2-(octadecyloxy)-

1000272-007

1,2,4-Oxadiazole, 5-methyl-3-(1piperidylmethyl)11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(3aminopropyl)-5,10-dihydro-

013450-73-2
013019-20-0

3-Heptanone, 2-methyl-

007726-08-1
002216-32-2
1000122-559

Decanamide, N-(2-hydroxyethyl)Heptane, 4-ethyl-

007496-81-3

Indolizine, 2-(4-methylphenyl)-

031083-60-0

Tricyclo[4.3.1.1(3,8)]undecane-1-carboxylic acid,
methyl ester

056114-69-3

Benzaldehyde, 2,5-bis[(trimethylsilyl)oxy]-

000275-51-4

Azulene

002919-23-5

Cyclobutanol
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1,3-Bis-(p-carbamoylmethylphenoxy)-2-propanol

The PCa model was evaluated to differentiate PCa patients from ccRCC patients and all
controls (i.e. PCa (-) and ccRCC (-). Via Jackknife cross-validation, the area under the ROC curve
is 0.834 with confidence interval 0.779 to 0.889 as shown in Figure 5. 2, which verified the
promising discrimination power of urinary VOCs in PCa diagnosis and revealed the prostate
cancer specificity of this 11 VOCs model.

Figure 5. 2 The ROC curve for VOC PCa diagnosis logistic model tested in 196 patients.
Then, ccRCC model was validated in discrimination ccRCC from PCa patients and all
controls (i.e. PCa (-) and ccRCC (-). Through the same cross-validation method, the AUC is 0.779
with confidence interval 0.707 to 0.851 as shown in Figure 5. 3, which proved the potential of
urinary VOCs in ccRCC diagnosis.
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Figure 5. 3 The ROC curve for VOC ccRCC diagnosis logistic model tested in 196 patients.

5.4 Discussion
The integrity and reliability of disease prediction models could be secured through careful
assessment of the validity of these models.178 There are two reasons to involve the careful
validation for the model developed from disease biomarkers, 1) overfitting issues with complex
models involving a large number of biomarkers, and 2) inter laboratory variation in assays used to
measure biomarkers.178 Those are also the reasons that we involved training-testing validation
method to evaluate the VOCs models for PCa diagnosis38 and ccRCC diagnosis and conducted the
cross examination of those two models with complexed patient groups. In this study, we cross
examined the performance of the PCa model predication and ccRCC prediction model with
different sample pool which presented a more complex medical scenarios. In the cross evaluation
of the PCa model, PCa negative group also contained patients who either have ccRCC or presented
to the facility with other kidney problem.

Likewise, the ccRCC was evaluated against patients

who appeared to have prostate problems.

The AUC 0.834 and 0.779 for validation sample pool
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with increased complexity has verified the potential of the VOCs model in PCa diagnosis and the
VOCs model in ccRCC diagnosis again. The results revealed the promising discrimination power
of those two VOCs model to differentiate the targeted cancer from a complex groups, which
provided a promising outlook of external validation of those VOCs based models in the near future.
A guidance of five phases in biomarker development for early detection of cancers were
proposed by Pepe et al179. As the investigation of VOCs based cancer prediction models in our
studies were conducted through mass spectrometry detection and innovative statistical machinelearning techniques, the development of VOCs models for PCa and ccRCC prediction could have
easily passed phase 1 (identify promising directions) and showed favorable results in phase 2
(clinical assay detects established disease). The further phase 3 (retrospective longitudinal
repository studies), phase 4 (prospective screening studies) and phase 5 (cancer control studies)
would be further pursued in extended internal validation and external validation of our studies.

5.5 Summary
This investigation supports the ability of urinary VOCs based diagnostic model to early
and non-invasive screening PCa and ccRCC patients. It further validates the clinical utility of
urinary VOCs based diagnostic model as the biomarker for PCa and ccRCC. In addition, the
external validation of those selected VOCs of PCa prediction model and ccRCC model in a larger
cohort would confirm the statistical significance in PCa and ccRCC screening.
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Chapter 6: Conclusions and Outlooks



This chapter states the concluding remarks and future directions of the research work in
this dissertation.
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6.1

Concluding remarks
As the metabolites produced by human body, urinary volatile organic compounds (VOCs)

of cancer patients and controls were investigated to develop VOCs based models for prostate
cancer (PCa) and clear cell renal carcinoma (ccRCC) diagnosis. Collaborating

with clinical

researchers and experts in statistics, we utilized advanced analytical chemistry to develop
innovative machine-learning VOCs based model for cancer early detection.

The ease of sample

preparation (i.e. Stir Bar Sorptive Extraction) and sensitive analytical instrumentation (Gas
Chromatography-Mass Spectrometry) allowed high throughput of VOC detection and that enabled
the research to unbiasedly search for significant VOCs for cancer early detection. Two urinary
VOCs based diagnostic models were developed: PCa model and ccRCC model.

The

development, validation and even cross examination of these models verified the great
discrimination power of urinary VOCs for differentiating cancer patients from controls, and
high/intermediate risk patients from low risk patients.

The performance of these models were

summarized in Table 6. 1. The PCa model was based on 11 significant VOCs; while the ccRCC
diagnosis model involved 15 VOCs In addition, we were able to show that VOCs based model
could be used for PCa risk assessment.
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Table 6. 1 The summary of VOCs based cancer diagnosis models for prostate cancer and renal cancer

VOCs Disease Models

PCa Model

PCa Risk
Assessment

ccRCC Model
# of VOCs overlapped
# of VOCs
between PCa and overlapped between
PCa risk assessment PCa and ccRCC

# of Dominated VOCs (p <
0.05)
Elevated in Cancer (or in
High/Intermediate risk)

254

23

79

Reduced in Cancer (or in
High/Intermediate risk)

282

44

91

11

11

15

AUC of training

0.92

0.86

0.87

AUC of testing

0.86

Sensitivity

96%

85%

93%

Specificity

80%

80%

77%

cross examination AUC in
complex sample pool

0.83

5

10

1

7

0

0

VOCs selected in final
model
# of VOCs

0.81

0.78
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The urinary VOC based metabolites approach could likely be adapted into a clinically
viable, highly sensitive, cost-effective portable diagnostic assay for PCa, ccRCC and even other
cancers. Nonetheless, the validity and effectiveness of those selected VOCs in PCa and ccRCC
diagnosis and PCa risk assessment need to be further confirmed in a larger cohort study.

6.2
Future directions
6.2.1 Larger cohort validation
The validity and effectiveness of those selected VOCs in PCa and ccRCC diagnosis and
PCa risk assessment need to be further confirmed in a larger cohort study. At the same time, there
are some further aims that should be included in the larger cohort evaluation of those VOCs based
cancer diagnosis models. Those include:
1) to build up risk score system for prostate cancer and renal cancer prediction;
2) to integrate urine sample screening system including VOCs profile detection, statistical
risk prediction and report production;
3) to estimate the reductions in cancer mortality and over-diagnosis of prostate cancer and
renal cancer which could be afforded by the VOCs based diagnosis models; and
4) to study factors (such as age, ethnicity, dilution factor, etc.) that could affect the prediction
ability of the models in cancer detection.
As VOCs reflect the physiological and metabolic status of the individual, they could be
further investigated in basic prostate cancer metabolomics research. These VOCs, that are only
produced in cancer cells or produced with significantly higher or lower levels than normal cells,
may therefore serve as biomarkers for the assessment, detection, monitoring, and even treatment
of disease. Though the study of the pathways affecting VOCs production is not within the scope
of this project, it is our goal to confirm those VOCs that are characteristic of cancers so that the
finding can be used in exploring pathway studies.
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6.2.2 Model validation with samples with/without treatment
The comparison about the behavior of VOCs before and after different treatments of
prostate cancer and renal caner is still unknown. And it would be the one of future direction of
VOCs research as cancer biomarker. In fact, the progression of cancers is different from each other
and the urinary VOCs profiles could play different roles in different types and stage of cancers.
Prostate cancer is a heterogeneous disease ranging from indolent to life threatening stages. The
monitoring of urinary VOCs profile with patients with localized tumor would be a reliable, fast,
low-cost and patients-friendly alternative other than invasive PSA serum test and DRE. For renal
cancer, the same type monitoring of urine VOCs profile could help those patients with kidney
disease, who may have higher incidence of renal cancer. Then, the track of urinary VOCs profile
after surgery and/or along the treatment, like the chemotherapy, would be helpful in early detection
of cancer recurrence and even the second cancer.
In the United States, prostate cancer (PCa) is the most common cancer and the third leading
cause of death in men. Routine PSA testing was discouraged by the United Service Preventive
Services Task Force in 2008 due to conflicting data questioning its value in reducing PCa-specific
mortality. Kidney cancer (KCa) accounts for more than 2% of cancer incidence and mortality in
the United States while there is no early detection method available. Our goal is to develop a
cost effective, accurate, and non-invasive cancer screening methods, and provide doctors
alternatives for more accurate diagnosis, and reduce cost in the healthcare system from ambiguous
and unnecessary recommendations for biopsy.

91

References
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Gallagher, M. et al. Analyses of volatile organic compounds from human skin. British
Journal of Dermatology 159, 780-791 (2008).
Ashley, D. L. et al. Determining volatile organic compounds in human blood from a large
sample population by using purge and trap gas chromatography/mass spectrometry.
Analytical chemistry 64, 1021-1029 (1992).
Phillips, M. et al. Variation in volatile organic compounds in the breath of normal humans.
Journal of Chromatography B: Biomedical Sciences and Applications 729, 75-88 (1999).
de Lacy Costello, B., Ratcliffe, N. M. & Smith, D. Volatile organic compounds (VOCs)
found in urine and stool. (Elsevier, Amsterdam, The Netherlands, 2013).
Amann, A. & Smith, D. Volatile biomarkers: non-invasive diagnosis in physiology and
medicine. (Newnes, 2013).
Shirasu, M. & Touhara, K. The scent of disease: volatile organic compounds of the human
body related to disease and disorder. The Journal of Biochemistry 150, 257-266 (2011).
Balseiro, S. & Correia, H. Is olfactory detection of human cancer by dogs based on major
histocompatibility complex-dependent odour components?–A possible cure and a
precocious diagnosis of cancer. Medical hypotheses 66, 270-272 (2006).
Cornu, J.-N., Cancel-Tassin, G., Ondet, V., Girardet, C. & Cussenot, O. Olfactory detection
of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. European
urology 59, 197-201 (2011).
Boedeker, E., Friedel, G. & Walles, T. Sniffer dogs as part of a bimodal bionic research
approach to develop a lung cancer screening. Interactive cardiovascular and thoracic
surgery 14, 511-515 (2012).
Willis, C. M., Britton, L. E., Harris, R., Wallace, J. & Guest, C. M. Volatile organic
compounds as biomarkers of bladder cancer: Sensitivity and specificity using trained
sniffer dogs. Cancer Biomarkers 8, 145-153 (2011).
Horvath, G., Andersson, H. & Paulsson, G. Characteristic odour in the blood reveals
ovarian carcinoma. BMC cancer 10, 643 (2010).
Wang, C. et al. Blood volatile compounds as biomarkers for colorectal cancer. Cancer
biology & therapy 15, 200-206 (2014).
Deng, C., Zhang, X. & Li, N. Investigation of volatile biomarkers in lung cancer blood
using solid-phase microextraction and capillary gas chromatography–mass spectrometry.
Journal of Chromatography B 808, 269-277 (2004).
Goldberg, E., Blendis, L. & Sandler, S. A gas chromatographic—mass spectrometric study
of profiles of volatile metabolites in hepatic encephalopathy. Journal of Chromatography
B: Biomedical Sciences and Applications 226, 291-299 (1981).
Manolis, A. The diagnostic potential of breath analysis. Clinical chemistry 29, 5-15 (1983).
Phillips, M. et al. Variation in volatile organic compounds in the breath of normal humans.
Journal of Chromatography B: Biomedical Sciences and Applications 729, 75-88 (1999).
Phillips, M. et al. Volatile organic compounds in breath as markers of lung cancer: a crosssectional study. The Lancet 353, 1930-1933 (1999).
Peng, G. et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nature
nanotechnology 4, 669 (2009).
Banday, K. M. et al. Use of urine volatile organic compounds to discriminate tuberculosis
patients from healthy subjects. Analytical chemistry 83, 5526-5534 (2011).
92

20
21
22

23
24
25
26

27
28
29
30
31
32
33
34
35
36
37

Sethi, S., Nanda, R. & Chakraborty, T. Clinical application of volatile organic compound
analysis for detecting infectious diseases. Clinical microbiology reviews 26, 462-475
(2013).
Khalid, T. et al. Urinary volatile organic compounds for the detection of prostate cancer.
PloS one 10, e0143283 (2015).
Monteiro, M. et al. Analysis of volatile human urinary metabolome by solid-phase
microextraction in combination with gas chromatography–mass spectrometry for
biomarker discovery: application in a pilot study to discriminate patients with renal cell
carcinoma. European Journal of Cancer 50, 1993-2002 (2014).
Weber, C. M. et al. Evaluation of a gas sensor array and pattern recognition for the
identification of bladder cancer from urine headspace. Analyst 136, 359-364 (2011).
Calderón-Santiago, M. et al. Human sweat metabolomics for lung cancer screening.
Analytical and bioanalytical chemistry 407, 5381-5392 (2015).
Choi, M.-J. & Oh, C.-H. 2nd dimensional GC-MS analysis of sweat volatile organic
compounds prepared by solid phase micro-extraction. Technology and Health Care 22,
481-488 (2014).
Garner, C. E., Smith, S., Bardhan, P., Ratcliffe, N. M. & Probert, C. A pilot study of faecal
volatile organic compounds in faeces from cholera patients in Bangladesh to determine
their utility in disease diagnosis. Transactions of the Royal Society of Tropical Medicine
and Hygiene 103, 1171-1173 (2009).
Garner, C. E. et al. Volatile organic compounds from feces and their potential for diagnosis
of gastrointestinal disease. The FASEB Journal 21, 1675-1688 (2007).
Batty, C. A., Cauchi, M., Lourenco, C., Hunter, J. O. & Turner, C. Use of the analysis of
the volatile faecal metabolome in screening for colorectal cancer. PLoS One 10, e0130301
(2015).
Schmidt, K. & Podmore, I. Current challenges in volatile organic compounds analysis as
potential biomarkers of cancer. Journal of biomarkers 2015 (2015).
Poli, D. et al. Determination of aldehydes in exhaled breath of patients with lung cancer by
means of on-fiber-derivatisation SPME–GC/MS. Journal of Chromatography B 878,
2643-2651 (2010).
Arthur, C. L. & Pawliszyn, J. Solid phase microextraction with thermal desorption using
fused silica optical fibers. Analytical chemistry 62, 2145-2148 (1990).
Zhang, Z. & Pawliszyn, J. Headspace solid-phase microextraction. Analytical chemistry
65, 1843-1852 (1993).
Pawliszyn, J. Solid phase microextraction: theory and practice. (John Wiley & Sons,
1997).
Pawliszyn, J. Handbook of solid phase microextraction. (Elsevier, 2011).
Baltussen, E., Sandra, P., David, F. & Cramers, C. Stir bar sorptive extraction (SBSE), a
novel extraction technique for aqueous samples: theory and principles. Journal of
Microcolumn Separations 11, 737-747 (1999).
Melo, L., Nogueira, A., Lancas, F. & Queiroz, M. Polydimethylsiloxane/polypyrrole stir
bar sorptive extraction and liquid chromatography (SBSE/LC-UV) analysis of
antidepressants in plasma samples. Analytica chimica acta 633, 57-64 (2009).
Soini, H., Bruce, K., Wiesler, D. & Novotny, M. Quantification of Volatiles in Mammalian
Urine by Stir Bar Sorptive Extraction (SBSE) Techniques and Gas Chromatography.

93

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Gao, Q. et al. Application of Urinary Volatile Organic Compounds (VOCs) for the
diagnosis of Prostate Cancer. Clinical Genitourinary Cancer (2019).
Tienpont, B., David, F., Bicchi, C. & Sandra, P. High capacity headspace sorptive
extraction. Journal of Microcolumn Separations 12, 577-584 (2000).
Ochiai, N. et al. Determination of trace amounts of off-flavor compounds in drinking water
by stir bar sorptive extraction and thermal desorption GC-MS. Analyst 126, 1652-1657
(2001).
Phillips, M. Method for the collection and assay of volatile organic compounds in breath.
Analytical biochemistry 247, 272-278 (1997).
Li, N. et al. Gas chromatography–mass spectrometric analysis of hexanal and heptanal in
human blood by headspace single-drop microextraction with droplet derivatization.
Analytical biochemistry 342, 318-326 (2005).
Peng, G. et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nature
nanotechnology 4, 669-673 (2009).
Nakhleh, M. K. et al. Diagnosis and Classification of 17 Diseases from 1404 Subjects via
Pattern Analysis of Exhaled Molecules. ACS nano (2016).
Filipiak, W. et al. TD-GC-MS analysis of volatile metabolites of human lung cancer and
normal cells in vitro. Cancer Epidemiology and Prevention Biomarkers 19, 182-195
(2010).
Fuchs, P., Loeseken, C., Schubert, J. K. & Miekisch, W. Breath gas aldehydes as
biomarkers of lung cancer. International Journal of Cancer 126, 2663-2670 (2010).
Ligor, T. et al. The analysis of healthy volunteers' exhaled breath by the use of solid-phase
microextraction and GC-MS. Journal of breath research 2, 046006 (2008).
Wehinger, A. et al. Lung cancer detection by proton transfer reaction mass-spectrometric
analysis of human breath gas. International Journal of Mass Spectrometry 265, 49-59
(2007).
Smith, D. & Španěl, P. Selected ion flow tube mass spectrometry (SIFT‐MS) for on‐
line trace gas analysis. Mass spectrometry reviews 24, 661-700 (2005).
Westhoff, M. et al. Ion mobility spectrometry for the detection of volatile organic
compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax
64, 744-748 (2009).
Di Natale, C. et al. Lung cancer identification by the analysis of breath by means of an
array of non-selective gas sensors. Biosensors and Bioelectronics 18, 1209-1218 (2003).
Hagleitner, C. et al. Smart single-chip gas sensor microsystem. Nature 414, 293 (2001).
Di Francesco, F., Fuoco, R., Trivella, M. G. & Ceccarini, A. Breath analysis: trends in
techniques and clinical applications. Microchemical journal 79, 405-410 (2005).
Oh, E. H., Song, H. S. & Park, T. H. Recent advances in electronic and bioelectronic noses
and their biomedical applications. Enzyme and microbial technology 48, 427-437 (2011).
Biasioli, F., Yeretzian, C., Märk, T. D., Dewulf, J. & Van Langenhove, H. Direct-injection
mass spectrometry adds the time dimension to (B) VOC analysis. TrAC Trends in
Analytical Chemistry 30, 1003-1017 (2011).
Röck, F., Barsan, N. & Weimar, U. Electronic nose: current status and future trends.
Chemical reviews 108, 705-725 (2008).
World Health Organization. CANCER CONTROL: A GLOBAL SNAPSHOT IN 2015.
World Health Organization; 2016.

94

58
59
60
61
62
63
64
65
66
67
68
69
70
71

72
73
74
75

Wood, S. L., Knowles, M. A., Thompson, D., Selby, P. J. & Banks, R. E. Proteomic studies
of urinary biomarkers for prostate, bladder and kidney cancers. Nature Reviews Urology
10, 206 (2013).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA: a cancer journal for
clinicians 68, 7-30 (2018).
Richter, J. et al. High-throughput tissue microarray analysis of cyclin E gene amplification
and overexpression in urinary bladder cancer. The American journal of pathology 157, 787794 (2000).
Rogers, M. A. et al. Proteomic profiling of urinary proteins in renal cancer by surface
enhanced laser desorption ionization and neural-network analysis: identification of key
issues affecting potential clinical utility. Cancer research 63, 6971-6983 (2003).
Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate
cancer progression. Nature 457, 910 (2009).
American
Cancer
Society.
Tests
for
Prostate
Cancer.
Access
at
www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/howdiagnosed.html#references on Mar 11, 2016.
Moyer, V. A. Screening for prostate cancer: US Preventive Services Task Force
recommendation statement. Annals of internal medicine 157, 120-134 (2012).
Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European
study. New England Journal of Medicine 360, 1320-1328 (2009).
Parekh, D. J. et al. A multi-institutional prospective trial in the USA confirms that the
4Kscore accurately identifies men with high-grade prostate cancer. European urology 68,
464-470 (2015).
Leyten, G. H. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene
fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. European
urology 65, 534-542 (2014).
Chun, F. K. et al. Prostate cancer gene 3 (PCA3): development and internal validation of a
novel biopsy nomogram. European urology 56, 659-668 (2009).
Loeb, S. & Catalona, W. J. The Prostate Health Index: a new test for the detection of
prostate cancer. Therapeutic advances in urology 6, 74-77 (2014).
Wojno, K. J. et al. Reduced rate of repeated prostate biopsies observed in ConfirmMDx
clinical utility field study. American health & drug benefits 7, 129 (2014).
Klein, E. A. et al. The single-parameter, structure-based IsoPSA assay demonstrates
improved diagnostic accuracy for detection of any prostate cancer and high-grade prostate
cancer compared to a concentration-based assay of total prostate-specific antigen: a
preliminary report. European Urology (2017).
Hessels, D. et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer
antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clinical Cancer
Research 13, 5103-5108 (2007).
Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia
10, 177IN171-188IN179 (2008).
Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. Pathology and genetics of tumours
of the urinary system and male genital organs. World Health Organization Classi (2004).
Ather, M. H., Masood, N. & Siddiqui, T. Current management of advanced and metastatic
renal cell carcinoma. Urology Journal 7, 1-9 (2010).

95

76
77
78
79
80
81

82
83
84
85
86
87
88
89
90
91
92

93
94
95
96

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016
WHO classification of tumours of the urinary system and male genital organs—part A:
renal, penile, and testicular tumours. European urology 70, 93-105 (2016).
Rodrigues, D. et al. Renal cell carcinoma: a critical analysis of metabolomic biomarkers
emerging from current model systems. Translational research 180, 1-11 (2017).
Lam, J. S., Leppert, J. T., Belldegrun, A. S. & Figlin, R. A. Novel approaches in the therapy
of metastatic renal cell carcinoma. World journal of urology 23, 202-212 (2005).
Najjar, Y. G. & Rini, B. I. Novel agents in renal carcinoma: a reality check. Therapeutic
advances in medical oncology 4, 183-194 (2012).
Wang, D. et al. Urinary volatile organic compounds as potential biomarkers for renal cell
carcinoma. Biomedical reports 5, 68-72 (2016).
Monteiro, M. et al. GC‐MS metabolomics‐based approach for the identification of a
potential VOC‐biomarker panel in the urine of renal cell carcinoma patients. Journal of
cellular and molecular medicine 21, 2092-2105 (2017).
Morrissey, J. J. et al. Evaluation of urine aquaporin-1 and perilipin-2 concentrations as
biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA oncology
1, 204-212 (2015).
Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. The Lancet 374, 239249 (2009).
Mostofi, F. Histologic typing of urinary bladder tumors. International histological
classification of tumors, 237-256 (1973).
Pashos, C. L., Botteman, M. F., Laskin, B. L. & Redaelli, A. Bladder cancer: epidemiology,
diagnosis, and management. Cancer practice 10, 311-322 (2002).
Pow-Sang, J. M. & Seigne, J. D. Contemporary management of superficial bladder cancer.
Cancer Control 7, 335-339 (2000).
Cummings, K. B., Barone, J. & Ward, W. S. Diagnosis and staging of bladder cancer. The
Urologic clinics of North America 19, 455-465 (1992).
Young, M. J. & Soloway, M. S. Office evaluation and management of bladder neoplasms.
Urologic Clinics of North America 25, 603-611 (1998).
CancerNet, P.
(Bethesda, Md: CancerNet PDQ, National Cancer Institute. Available
at: http …, 2001).
Burchardt, M. et al. Current concepts in biomarker technology for bladder cancers. Clinical
chemistry 46, 595-605 (2000).
Zlotta, A. R. & Schulman, C. C. Biological markers in superficial bladder tumors and their
prognostic significance. Urologic Clinics of North America 27, 179-189 (2000).
Poulakis, V. et al. A comparison of urinary nuclear matrix protein‐22 and bladder tumour
antigen tests with voided urinary cytology in detecting and following bladder cancer: the
prognostic value of false‐positive results. BJU international 88, 692-701 (2001).
Khalid, T. et al. A pilot study combining a GC-sensor device with a statistical model for
the identification of bladder cancer from urine headspace. PloS one 8, e69602 (2013).
Lu, N. Z. et al. International Union of Pharmacology. LXV. The pharmacology and
classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid,
progesterone, and androgen receptors. Pharmacological reviews 58, 782-797 (2006).
Roy, A. et al. Regulation of androgen action. Vitamins & Hormones 55, 309-352 (1998).
Corbin, J. M. & Ruiz-Echevarría, M. J. One-Carbon Metabolism in Prostate Cancer: The
Role of Androgen Signaling. International journal of molecular sciences 17, 1208 (2016).
96

97
98
99
100
101
102
103
104

105
106
107
108
109
110
111
112
113
114
115

Stover, P. J. One-carbon metabolism–genome interactions in folate-associated pathologies.
The Journal of nutrition 139, 2402-2405 (2009).
Mentch, S. J. & Locasale, J. W. One‐carbon metabolism and epigenetics: understanding
the specificity. Annals of the New York Academy of Sciences 1363, 91-98 (2016).
Locasale, J. W. Serine, glycine and one-carbon units: cancer metabolism in full circle.
Nature reviews Cancer 13, 572-583 (2013).
Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer
cell 29, 104-116 (2016).
Ottaviani, S. et al. Characterisation of the androgen regulation of glycine Nmethyltransferase in prostate cancer cells. Journal of molecular endocrinology 51, 301312 (2013).
Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate
cancer progression. Nature 457, 910-914 (2009).
Khan, A. P. et al. The role of sarcosine metabolism in prostate cancer progression.
Neoplasia 15, 491IN496-501IN413 (2013).
Green, T., Chen, X., Ryan, S., Asch, A. S. & Ruiz‐Echevarría, M. J. TMEFF2 and
SARDH cooperate to modulate one‐carbon metabolism and invasion of prostate cancer
cells. The Prostate 73, 1561-1575 (2013).
Massie, C. E. et al. The androgen receptor fuels prostate cancer by regulating central
metabolism and biosynthesis. The EMBO journal 30, 2719-2733 (2011).
Barfeld, S. J., Itkonen, H. M., Urbanucci, A. & Mills, I. G. Androgen-regulated metabolism
and biosynthesis in prostate cancer. Endocrine-related cancer 21, T57-T66 (2014).
Tennakoon, J. B. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC1α-mediated metabolic switch. Oncogene 33, 5251-5261 (2014).
Tsouko, E. et al. Regulation of the pentose phosphate pathway by an androgen receptor–
mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 3,
e103 (2014).
Costello, L., Franklin, R. & Feng, P. Mitochondrial function, zinc, and intermediary
metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5, 143153 (2005).
Costello, L., Feng, P., Milon, B., Tan, M. & Franklin, R. Role of zinc in the pathogenesis
and treatment of prostate cancer: critical issues to resolve. Prostate cancer and prostatic
diseases 7, 111-117 (2004).
Franz, M.-C. et al. Zinc transporters in prostate cancer. Molecular aspects of medicine 34,
735-741 (2013).
Asgari, Y., Zabihinpour, Z., Salehzadeh-Yazdi, A., Schreiber, F. & Masoudi-Nejad, A.
Alterations in cancer cell metabolism: the Warburg effect and metabolic adaptation.
Genomics 105, 275-281 (2015).
Costello, L. & Franklin, R. Novel role of zinc in the regulation of prostate citrate
metabolism and its implications in prostate cancer. The Prostate 35, 285-296 (1998).
Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer
pathogenesis. Nature Reviews Cancer 7, 763-777 (2007).
Swinnen, J. V., Brusselmans, K. & Verhoeven, G. Increased lipogenesis in cancer cells:
new players, novel targets. Current Opinion in Clinical Nutrition & Metabolic Care 9, 358365 (2006).

97

116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134

Igal, R. A. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell
proliferation, programmed cell death and transformation to cancer. Carcinogenesis 31,
1509-1515 (2010).
Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in
clear cell renal tumors. Clinical cancer research 14, 4726-4734 (2008).
Du, W. et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid
metabolism. Nature communications 8, 1769 (2017).
Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocrine reviews 25,
276-308 (2004).
Deep, G. & Schlaepfer, I. R. Aberrant lipid metabolism promotes prostate cancer: role in
cell survival under hypoxia and extracellular vesicles biogenesis. International journal of
molecular sciences 17, 1061 (2016).
Griffin, J. E. Androgen resistance—the clinical and molecular spectrum. New England
Journal of Medicine 326, 611-618 (1992).
Yoshii, Y. et al. Fatty acid synthase is a key target in multiple essential tumor functions of
prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy
outcome. PloS one 8, e64570 (2013).
Eidelman, E., Twum-Ampofo, J., Ansari, J. & Siddiqui, M. M. The Metabolic Phenotype
of Prostate Cancer. Frontiers in oncology 7, 131 (2017).
Tan, L. T.-H. et al. Targeting membrane lipid a potential cancer cure? Frontiers in
pharmacology 8 (2017).
Ekwueme, D. U., Stroud, L. A. & Chen, Y. Peer Reviewed: Cost Analysis of Screening
for, Diagnosing, and Staging Prostate Cancer Based on a Systematic Review of Published
Studies. Preventing chronic disease 4 (2007).
Aubry, W. et al. Budget impact model: epigenetic assay can help avoid unnecessary
repeated prostate biopsies and reduce healthcare spending. American health & drug
benefits 6, 15 (2013).
Van Neste, L. et al. The epigenetic promise for prostate cancer diagnosis. The Prostate 72,
1248-1261 (2012).
HB, S. What’s the downside to a biopsy? Prostate Knowledge, Harvard Medical School
publications.
https://www.harvardprostateknowledge.org/whats-the-downside-to-abiopsy. Accessed May 23, 2018.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. cell 144, 646674 (2011).
Silva, C. L., Passos, M. & Câmara, J. S. Solid phase microextraction, mass spectrometry
and metabolomic approaches for detection of potential urinary cancer biomarkers—a
powerful strategy for breast cancer diagnosis. Talanta 89, 360-368 (2012).
Willis, C. M. et al. Olfactory detection of human bladder cancer by dogs: proof of principle
study. Bmj 329, 712 (2004).
Taverna, G. et al. Olfactory system of highly trained dogs detects prostate cancer in urine
samples. The Journal of urology 193, 1382-1387 (2015).
Sonoda, H. et al. Colorectal cancer screening with odour material by canine scent detection.
Gut 60, 814-819 (2011).
Matsumura, K. et al. Urinary volatile compounds as biomarkers for lung cancer: a proof of
principle study using odor signatures in mouse models of lung cancer. PloS one 5, e8819
(2010).
98

135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153

Amann, A. et al. The human volatilome: volatile organic compounds (VOCs) in exhaled
breath, skin emanations, urine, feces and saliva. Journal of breath research 8, 034001
(2014).
Fan, J. & Lv, J. Sure independence screening for ultrahigh dimensional feature space.
Journal of the Royal Statistical Society: Series B (Statistical Methodology) 70, 849-911
(2008).
Tibshirani, R. Regression shrinkage and selection via the lasso. Journal of the Royal
Statistical Society. Series B (Methodological), 267-288 (1996).
Kleinbaum, D. a. K., M. . Logistic Regression, A Self-Learning Text. 3rd Edition., (2010).
Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27-38 (1993).
López-Ratón, M., Rodríguez-Álvarez, M. X., Cadarso-Suárez, C. & Gude-Sampedro, F.
OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. Journal
of Statistical Software 61, 1-36 (2014).
Team, R. C. R: A language and environment for statistical computing, <https://www.Rproject.org/> (2017).
Chistiakov, D. A., Myasoedova, V. A., Grechko, A. V., Melnichenko, A. A. & Orekhov,
A. N. in Seminars in cancer biology.
(Elsevier).
Stewart, G. D. et al. Clinical utility of an epigenetic assay to detect occult prostate cancer
in histopathologically negative biopsies: results of the MATLOC study. The Journal of
urology 189, 1110-1116 (2013).
Trock, B. J. in Urologic Oncology: Seminars and Original Investigations. 572-581
(Elsevier).
Crowe, F. L. et al. Fatty acid composition of plasma phospholipids and risk of prostate
cancer in a case-control analysis nested within the European Prospective Investigation into
Cancer and Nutrition–. The American journal of clinical nutrition 88, 1353-1363 (2008).
Epstein, M. M. et al. Dietary fatty acid intake and prostate cancer survival in Örebro
County, Sweden. American journal of epidemiology 176, 240-252 (2012).
Kim, S. et al. Myristoylation of Src kinase mediates Src induced and high fat diet
accelerated prostate tumor progression in mice. Journal of Biological Chemistry, jbc.
M117. 798827 (2017).
Nadler, M. J., Harrison, M. L., Ashendel, C. L., Cassady, J. M. & Geahlen, R. L. Treatment
of T cells with 2-hydroxymyristic acid inhibits the myristoylation and alters the stability of
p56lck. Biochemistry 32, 9250-9255 (1993).
Noguchi, M. et al. Induction of cellular and humoral immune responses to tumor cells and
peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide
vaccination. The Prostate 57, 80-92 (2003).
Harada, M., Noguchi, M. & Itoh, K. Target molecules in specific immunotherapy against
prostate cancer. International journal of clinical oncology 8, 193-199 (2003).
National Center for Biotechnology Information. PubChem Compound Database;
CID=73219, h. p. n. n. n. g. c.
Zhong, C., Yang, S., Huang, J., Cohen, M. B. & Roy-Burman, P. Aberration in the
expression of the retinoid receptor, RXRα, in prostate cancer. Cancer biology & therapy
2, 179-184 (2003).
Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. & Stampfer, M. J. Prospective study
of sex hormone levels and risk of prostate cancer. JNCI: Journal of the National Cancer
Institute 88, 1118-1126 (1996).
99

154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172

Cooperberg, M. R. Prostate cancer risk assessment: choosing the sharpest tool in the shed.
Cancer: Interdisciplinary International Journal of the American Cancer Society 113,
3062-3066 (2008).
Scher, H. I. & Heller, G. Clinical states in prostate cancer: toward a dynamic model of
disease progression. Urology 55, 323-327 (2000).
Chang, A. J., Autio, K. A., Roach III, M. & Scher, H. I. High-risk prostate cancer—
classification and therapy. Nature reviews Clinical oncology 11, 308 (2014).
Fleming, C. et al. A decision analysis of alternative treatment strategies for clinically
localized prostate cancer. Jama 269, 2650-2658 (1993).
Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in
primary treatment of localized prostate cancer. Journal of Clinical Oncology 28, 1117
(2010).
Wilt, T. J. et al. Systematic review: comparative effectiveness and harms of treatments for
clinically localized prostate cancer. Annals of internal medicine 148, 435-448 (2008).
Thompson, I. M. et al. Assessing prostate cancer risk: results from the Prostate Cancer
Prevention Trial. Journal of the National Cancer Institute 98, 529-534 (2006).
Tomlins, S. A. et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk
in men with elevated serum PSA. Science translational medicine 3, 94ra72-94ra72 (2011).
Rastinehad, A. R. et al. D'Amico risk stratification correlates with degree of suspicion of
prostate cancer on multiparametric magnetic resonance imaging. The Journal of urology
185, 815-820 (2011).
Dufort, I., Soucy, P. & Lacoste, L. Comparative biosynthetic pathway of androstenol and
androgens. The Journal of steroid biochemistry and molecular biology 77, 223-227 (2001).
Devgan, S. A. et al. Genetic variation of 3β‐hydroxysteroid dehydrogenase type II in
three racial/ethnic groups: Implications for prostate cancer risk. The Prostate 33, 9-12
(1997).
Thomas, L. N. et al. Differential alterations in 5α‐reductase type 1 and type 2 levels
during development and progression of prostate cancer. The Prostate 63, 231-239 (2005).
Forman, B. M. et al. Androstane metabolites bind to and deactivate the nuclear receptor
CAR-β. Nature 395, 612 (1998).
Moore, L. B. et al. Orphan nuclear receptors constitutive androstane receptor and pregnane
X receptor share xenobiotic and steroid ligands. Journal of Biological Chemistry 275,
15122-15127 (2000).
Fujimura, T. et al. Clinical significance of steroid and xenobiotic receptor and its targeted
gene CYP3A4 in human prostate cancer. Cancer science 103, 176-180 (2012).
Hernandez, D. J., Nielsen, M. E., Han, M. & Partin, A. W. Contemporary evaluation of the
D’amico risk classification of prostate cancer. Urology 70, 931-935 (2007).
Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. & Scardino, P. T. A
preoperative nomogram for disease recurrence following radical prostatectomy for prostate
cancer. JNCI: Journal of the National Cancer Institute 90, 766-771 (1998).
Cooperberg, M. R. et al. The University of California, San Francisco Cancer of the Prostate
Risk Assessment score: a straightforward and reliable preoperative predictor of disease
recurrence after radical prostatectomy. The Journal of urology 173, 1938-1942 (2005).
Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. The Lancet 373, 11191132 (2009).

100

173
174
175

176
177
178
179

Weiss, R. H. & Kim, K. Metabolomics in the study of kidney diseases. Nature Reviews
Nephrology 8, 22 (2012).
McMahon, G. M. & Waikar, S. S. Biomarkers in nephrology: core curriculum 2013.
American Journal of Kidney Diseases 62, 165-178 (2013).
Andreoli, R., Manini, P., Corradi, M., Mutti, A. & Niessen, W. M. Determination of
patterns of biologically relevant aldehydes in exhaled breath condensate of healthy subjects
by liquid chromatography/atmospheric chemical ionization tandem mass spectrometry.
Rapid Communications in Mass Spectrometry 17, 637-645 (2003).
Liu, H. et al. Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion
injury. American Journal of Physiology-Renal Physiology 295, F942-F949 (2008).
Nemer, M. J. & Elwyn, D. The conversion of serine to ethanolamine and its derivatives in
the rat. Journal of Biological Chemistry 235, 2070-2074 (1960).
Taylor, J. M., Ankerst, D. P. & Andridge, R. R. Validation of biomarker-based risk
prediction models. Clinical Cancer Research 14, 5977-5983 (2008).
Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. Journal
of the National Cancer Institute 93, 1054-1061 (2001).

101

Vita
Qin Gao earned her Bachelor of Science degree in pharmacy from China Pharmaceutical
University in 2010. In 2013, she received her Master of Science degree in pharmacology from
China Pharmaceutical University. Then, she joined UTEP’s doctoral program in chemistry and
biochemistry in 2014.
She was the recipient of Wiemer Family Student Endowment for Excellence Scholarship,
Dodson Research Grant, and Dr. Keelung Hong Chemistry Graduate Research Fellowship.
She has presented her research at several conferences including 2016 Graduate Research
Expo in UTEP, 2017 Pittcon Conference and Expo, 2017 BBRC (Border Biomedical Research
Center) Symposium, 2017 annual meeting of SBUR (Society for Basic Urologic Research), 2018
Chemistry Day Symposium of UTEP, and 2018 66th ASMS (American Society for Mass
Spectrometry) Conference. Her work has been published on Genitourinary Cancer.
While pursuing her degree, she worked as a teaching assistant and research associate for
the Department of Chemistry and Biochemistry. After PhD graduation, she will continue to work
on metabolomics study for disease diagnosis and prognosis and push forward the
commercialization of her findings in research.
Her dissertation, “Application of Urinary Metabolites in Cancer Detection”, was
supervised by Dr. Wen-Yee Lee.

This dissertation was typed by Qin Gao (Email: qgao@miners.utep.edu, qingaocn@live.com ).

102

